var title_f0_48_768="Bullous impetigo";
var content_f0_48_768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Bullous impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_768=[""].join("\n");
var outline_f0_48_768=null;
var title_f0_48_769="Pemphigus vulgaris - oral";
var content_f0_48_769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris - oral lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions on the&nbsp;palate in a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_769=[""].join("\n");
var outline_f0_48_769=null;
var title_f0_48_770="Cecum";
var content_f0_48_770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cecum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cecum seen during colonoscopy. The crescent-shaped structure is the appendiceal orifice (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_770=[""].join("\n");
var outline_f0_48_770=null;
var title_f0_48_771="Distal phalanx fracture of great toe";
var content_f0_48_771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Nondisplaced distal phalanx fracture of great toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the middle view, note the apparent lucency running obliquely across the medial sesamoid of the great toe (black arrow). This is an illusion created by the overlying cortex of the first metatarsal, and does not represent a fracture. This is supported by the normal appearance of the sesamoid on the other views.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_771=[""].join("\n");
var outline_f0_48_771=null;
var title_f0_48_772="Factor XIII concentrates: Drug information";
var content_f0_48_772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Factor XIII concentrates: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/62/44003?source=see_link\">",
"    see \"Factor XIII concentrates: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12871939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corifact&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11595707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11595767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Congenital factor XIII deficiency:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 40 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Dose adjustment should be based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom&reg; activity assay) and clinical response; repeat every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     One trough level of &lt;5%: Increase dosage by 5 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Trough level of 5% to 20%: No dosage change",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Two trough levels of &gt;20%: Decrease dosage by 5 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     One trough level of &gt;25%: Decrease dosage by 5 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Perioperative management of surgical bleeding:",
"     </i>",
"     Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If time since last prophylactic dose &le;7 days: Additional dose may not be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If time since last prophylactic dose 8-21 days: Additional partial or full dose may be necessary based on factor XIII activity level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If time since last prophylactic dose 21-28 days: Administer full prophylactic dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11595766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11595768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11595776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11595777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12871940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corifact&reg;: Exact potency labeled on each vial [heat treated; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11595705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11595769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.V. infusion at a rate not to exceed 4 mL/minute. Product should be brought to room temperature prior to infusing. Administer through a separate infusion line.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11595708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis against bleeding episodes and management of perioperative surgical bleeding in patients with congenital factor XIII deficiency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11595805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor XIII may be confused with Factor VIII",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11595749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising, erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hematoma, thrombin-antithrombin levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, joint inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute ischemia, anaphylaxis, factor XIII inhibitory antibodies, infection,  thromboembolism",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11595712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylaxis or severe systemic reactions to human plasma-derived products or hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11595713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: The development of factor XIII inhibitory antibodies has been reported.  Factor XIII inhibitory antibodies should be measured when clinical response (breakthrough bleeding) and/or factor XIII trough levels are suboptimal after apparent adequate dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use; discontinue immediately if develops and initiate appropriate management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic events: Thromboembolic events have been reported; pregnant women may be at increased risk due to hypercoagulable state. Use with caution in patients with known risk factors for thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Vaccination with hepatitis A and hepatitis B vaccines is  recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11595709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11595710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in pregnant women only when benefit exceeds potential risk to the fetus. Thromboembolic events have been reported with use of factor XIII; pregnant women may be at increased risk due to hypercoagulable state.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11595711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16338855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if factor XIII concentrate (human) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering factor XIII concentrate (human) to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Corifact Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-1600 unit (1): $9.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11595772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Factor XIII trough levels in conjunction with clinical response to assess efficacy (ie, approximately every 28 days for prophylaxis, during and after surgery for perioperative management of surgical bleeding). Factor XIII inhibitory antibodies if inadequate clinical response and/or factor XIII trough levels are suboptimal. Signs/symptoms of hypersensitivity reactions, thrombotic events, and infection.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fibrogammin (AT, BE, DE, GR);",
"     </li>",
"     <li>",
"      Fibrogammin P (AR, BR, CH, GB, IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11595756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Factor XIII (FXIII) is an endogenous plasma glycoprotein found in platelets, monocytes and macrophages that is converted to activated factor XIII (FXIIIa) in the presence of calcium ions.  Once activated, FXIIIa cross-links fibrin and cross-links plasmin inhibitor to protect and strengthen the hemostatic platelet plug.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11595758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of effect: Plasma levels of FXIII: ~28 days; FXIII activity maintained at &ge;5% in &ge;97% of patients and &ge;10% in &ge;85% of patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 51.1 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Factor XIII, a proenzyme, is converted to activated factor XIII",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Children (&lt;16): 5.7 days; Adults: 7.1 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1.7 hours postinfusion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hsieh L and Nugent D, &ldquo;Factor XIII Deficiency,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2008, 14(6):1190-200.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karimi M, Bereczky Z, Cohan N, et al, &ldquo;Factor XIII Deficiency,&rdquo;",
"      <i>",
"       Semin Thromb Hemost",
"      </i>",
"      , 2009, 35(4):426-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/772/abstract-text/19598071/pubmed\" id=\"19598071\" target=\"_blank\">",
"        19598071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16473 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_772=[""].join("\n");
var outline_f0_48_772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12871939\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595707\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595766\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595776\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595777\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12871940\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595705\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595769\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595708\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595805\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595749\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299310\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608729\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595709\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595710\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338855\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322888\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595772\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992821\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595758\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/62/44003?source=related_link\">",
"      Factor XIII concentrates: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_773="Chlorpheniramine and phenylephrine: Drug information";
var content_f0_48_773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/41/21141?source=see_link\">",
"    see \"Chlorpheniramine and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ed ChlorPed D [OTC];",
"     </li>",
"     <li>",
"      Ed-A-Hist&trade; [OTC];",
"     </li>",
"     <li>",
"      LoHist [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PEH [OTC];",
"     </li>",
"     <li>",
"      nasohist&trade; [OTC];",
"     </li>",
"     <li>",
"      NoHist LQ [OTC];",
"     </li>",
"     <li>",
"      NoHist [OTC] [DSC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Sinus + Allergy [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Virdec [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antihistamine/decongestant:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Chlorpheniramine dosing in terms of chlorpheniramine maleate; phenylephrine dosing in terms of phenylephrine hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid: Chlorpheniramine 4 mg and phenylephrine 10 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chlorpheniramine 3-4 mg and phenylephrine 10 mg: One tablet every 4-6 hours (maximum: 6 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antihistamine/decongestant:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Chlorpheniramine dosing in terms of chlorpheniramine maleate; phenylephrine dosing in terms of phenylephrine hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 2-5 years:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 1 mg and phenylephrine 2.5 mg per 1 mL: 1 mL every 4-6 hours (maximum: 4 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg and phenylephrine 5 mg per 1 mL: 0.5 mL every 4 hours (maximum: 3 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 6-11 years:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 1 mg and phenylephrine 2-2.5 mg per 1 mL:  2 mL every 4-6 hours (maximum: 8 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 1-2 mg and phenylephrine 3.5-5 mg per 1 mL: 1 mL every 4-6 hours (maximum: 6 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 1 mg and phenylephrine 2.5 mg per 5 mL: 10 mL every 4 hours (maximum: 60 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 4 mg and phenylephrine 10 mg per 5 mL: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Chlorpheniramine 3-4 mg and phenylephrine 10 mg: One-half tablet every 4-6 hours (maximum: 3 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 years:",
"     </i>",
"     Refer to adult dosing:",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed-A-Hist&trade;: Chlorpheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg per 5 mL (473 mL) [sugar free; contains ethanol 5%, propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NoHist LQ: Chlorpheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg per 5 mL (473 mL) [ethanol free, sugar free; contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed ChlorPed D: Chlorpheniramine maleate 2 mg and phenylephrine hydrochloride 5 mg per 1 mL (60 mL) [ethanol free, sugar free; contains propylene glycol; applesauce flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist: Chlorpheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 1 mL (60 mL) [dye free, ethanol free, sugar free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     nasohist&trade;: Chlorpheniramine maleate 1 mg and phenylephrine hydrochloride 2 mg per 1 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Virdec: Chlorpheniramine maleate 1 mg and phenylephrine hydrochloride 3.5 mg per 1 mL (30 mL) [ethanol free, sugar free; contains propylene glycol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&reg; Children&rsquo;s Cold &amp; Allergy: Chlorpheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [contains benzoic acid, sodium 3 mg/5 mL; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Chlorpheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed-A-Hist&trade;: Chlorpheniramine maleate 3 mg and phenylephrine hydrochloride 10 mg [contains tartrazine; scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxichlor PEH: Chlorpheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NoHist: Chlorpheniramine maleate 3 mg and phenylephrine hydrochloride 10 mg [scored] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of upper respiratory conditions such as nasal congestion, runny nose, and sneezing due to the common cold, hay fever, or allergic or vasomotor rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rynatan&reg; may be confused with Rynatuss&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine, phenylephrine, or any component of the formulation; severe hypertension; severe cardiovascular disease; use with or within 2 weeks of discontinuing MAO inhibitor; narrow-angle glaucoma; urinary retention; peptic ulcer disease; acute asthma attack; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9729984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F150105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Cardec Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3.5 mg/mL (30 mL): $22.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Dallergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2 mg/mL (30 mL): $18.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Ed A-Hist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg/5 mL (473 mL): $19.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Ed ChlorPed D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-5 mg/mL (60 mL): $23.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Nasohist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2 mg/mL (30 mL): $24.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Triaminic Cold/Allergy Child Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5 mg/5 mL (118 mL): $5.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Rescon-Jr Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-20 mg (90): $120.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-20 mg (100): $105.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Actifed Cold/Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg (12): $2.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ed A-Hist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg (100): $27.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ed-A-Hist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-10 mg (100): $40.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phenabid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10 mg (100): $199.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sudafed PE Sinus/Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg (24): $4.76",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rhinathiol Antirhinitis (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8685 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_773=[""].join("\n");
var outline_f0_48_773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150120\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150111\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150116\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150112\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150101\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150126\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150104\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150093\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150117\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150096\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150107\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729984\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150105\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038560\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150103\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/41/21141?source=related_link\">",
"      Chlorpheniramine and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_774="Leuprolide: Patient drug information";
var content_f0_48_774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Leuprolide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     see \"Leuprolide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"     see \"Leuprolide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eligard&reg;;",
"     </li>",
"     <li>",
"      Lupron Depot-Ped&reg;;",
"     </li>",
"     <li>",
"      Lupron Depot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eligard&reg;;",
"     </li>",
"     <li>",
"      Lupron&reg;;",
"     </li>",
"     <li>",
"      Lupron&reg; Depot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia caused by fibroids of the uterus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to delay puberty in children who are maturing too early.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to leuprolide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have vaginal bleeding and have not been to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Disease signs may get worse before getting better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain, blood in urine, and trouble passing urine. Most often gets better 1 to 2 weeks after care has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain after 2 to 4 weeks of care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal bleeding for more than 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin or a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eligard&reg;, Lupron Depot-Ped&reg;, Lupron Depot&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Leuprolide acetate 5 mg/mL solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials at room temperature or in the refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11211 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_774=[""].join("\n");
var outline_f0_48_774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187454\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187455\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019062\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019061\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019066\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019067\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019069\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019064\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019065\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019070\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019071\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=related_link\">",
"      Leuprolide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=related_link\">",
"      Leuprolide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_775="Management of Elapidae (coral snake) bites in the United States";
var content_f0_48_775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Elapidae (coral snake) bites in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     Allen C Cheng, MB, BS, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     Steven A Seifert, MD, FAACT, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/775/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/775/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/48/775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coral snake bites occur rarely in the United States. Successful treatment requires prompt transfer of the snake bite victim to definitive medical care, careful clinical assessment, and timely administration of antivenom in selected patients. Consultation with a medical toxicologist or other physician with experience in managing poisonous snake bites is recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222.",
"   </p>",
"   <p>",
"    The clinical evaluation and management of coral snake bites is reviewed here. The principles of management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) snake bites and snake bites outside the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=see_link\">",
"     \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elapidae (coral snake) bites are far less common in the United States than Crotalinae (eg, rattlesnake, water moccasin [cottonmouth], or copperhead) bites, although fatalities are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/1\">",
"     1",
"    </a>",
"    ]. The coral snake is primarily found in the states of Texas and Florida, including species of the genera Micruroides and Micrurus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elapid envenomation typically causes neurotoxicity (manifesting as muscular weakness), respiratory depression, or respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/3\">",
"     3",
"    </a>",
"    ]. Muscle weakness may include bulbar paralysis (ptosis, dysarthria, dysphagia, and hypersalivation) and fasciculations. Seizures have been reported in children.",
"   </p>",
"   <p>",
"    Nonspecific symptoms, such as nausea, vomiting, dizziness, and abdominal pain, may also occur.",
"   </p>",
"   <p>",
"    Although swelling at the bite site may be present, it is usually less pronounced than in patients with Crotalinae (eg, rattlesnake, water moccasin [cottonmouth], or copperhead) envenomations. Significant local tissue damage and coagulopathy are",
"    <strong>",
"     not",
"    </strong>",
"    associated with elapid envenomation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FIRST AID",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial first aid of a snake bite is directed at reducing the spread of venom and expediting transfer to an appropriate medical center according to the following general principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the patient from the snake's territory, and keep him or her warm, at rest, and calm.",
"     </li>",
"     <li>",
"      Immobilize the injured body part in a functional position below the level of the heart. Do",
"      <strong>",
"       not",
"      </strong>",
"      apply",
"      <span class=\"nowrap\">",
"       constrictive/tourniquet",
"      </span>",
"      dressings.",
"     </li>",
"     <li>",
"      Cleanse the wound.",
"     </li>",
"     <li>",
"      Withhold alcohol and drugs that may cause altered mental status.",
"     </li>",
"     <li>",
"      Attempt to identify the snake without endangering the patient or rescuer. A digital photo taken at a safe distance may be useful. Snake parts should not be handled directly.",
"     </li>",
"     <li>",
"      Transport the patient to the nearest medical facility as quickly as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pressure immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure immobilization is used to delay systemic absorption of snake venom in areas where neurotoxic elapids are common. It is not used routinely in the United States, where local tissue toxicity from pit viper envenomation is most common. However, it may be useful for bites by coral snakes and when there may be significant delays in transfer to medical facilities (",
"    <a class=\"graphic graphic_figure graphicRef68766 \" href=\"UTD.htm?35/62/36842\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link&amp;anchor=H4#H4\">",
"     \"Principles of snake bite management worldwide\", section on 'Pressure immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Venomous or nonvenomous?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coral snakes have small heads and fangs, but can be identified by their brightly colored bands. They can be differentiated from similar nonvenomous snakes by their banding patterns. Venomous coral snakes within the United States have red and yellow bands adjacent to each other (remembered by the phrase \"red and yellow, kill a fellow; red and black, friend of Jack\" or \"venom lack\").",
"   </p>",
"   <p>",
"    Misidentification (particularly in an emergency situation) may have potentially serious outcomes, and patients with possible envenomation should be observed closely [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Techniques to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;First aid techniques not proven to be beneficial and possibly harmful are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\", section on 'Techniques to avoid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of coral snake envenomation are at risk for delayed neurotoxicity and respiratory failure and warrant prolonged observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected coral snake envenomation, serial detailed neurologic examinations should be performed for at least 12 hours because onset of neurologic findings may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/5\">",
"     5",
"    </a>",
"    ]. Important clinical findings include the presence of motor weakness, particularly involving cranial nerves (ptosis, diplopia, bulbar palsy).",
"   </p>",
"   <p>",
"    Patients with clinical evidence of ventilatory failure warrant prompt endotracheal intubation.",
"   </p>",
"   <p>",
"    Patients without clinical evidence of ventilatory failure should undergo serial assessments of their ability to protect the airway and of ventilatory function given the risk of progressive neuromuscular weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coral snake envenomation does not cause coagulopathy or major local tissue effects. Measurement of hematologic and coagulation indices, and assessment for rhabdomyolysis is not indicated.",
"   </p>",
"   <p>",
"    Although the decision to perform endotracheal intubation and institute mechanical ventilation should be made on clinical grounds (including the need for airway protection associated with bulbar palsy), ancillary studies may provide additional objective information to augment serial clinical assessment in some patients. Options include pulmonary function testing, noninvasive capnography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood gas measurement. Continuous pulse oximetry is advisable, but is insensitive for detection of respiratory failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function testing &ndash; Serial measurements of pulmonary function, especially maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and forced vital capacity (FVC), can identify the presence and degree of respiratory muscle weakness. Serial measures of pulmonary function (instead of using one measure at one point in time) can be used as rough guidelines, especially when the respiratory decline is acute in children under six years of age. MIP can be obtained even when a lack of cooperation does not allow measurement of MEP or FVC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link&amp;anchor=H5#H5\">",
"       \"Tests of respiratory muscle strength\", section on 'Interpretation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"       \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ventilatory support is indicated when the FVC is less than 50 percent of predicted, when the MIP is less negative than -30 cmH2O (eg, -20 cmH2O), or when the MEP is below 40 cmH2O. The diminished MIP indicates a high risk for hypercapnia, while the low MEP indicates inadequate cough strength and risk for secretion retention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capnography &ndash; Capnography measures end-tidal CO2 (EtCO2) and respiratory rate with each breath in spontaneously breathing patients. Continuous capnography provides instantaneous feedback on the clinical status of the patient and can provide early detection of hypercarbia in victims of coral snake envenomation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H14#H14\">",
"       \"Carbon dioxide monitoring (capnography)\", section on 'Acute respiratory distress'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood gas measurement &ndash; Arterial or venous blood gas may also be used to assess the degree of respiratory acidosis in patients with weakness or declining clinical status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link&amp;anchor=H12584090#H12584090\">",
"       \"Simple and mixed acid-base disorders\", section on 'Respiratory acidosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis should be administered to snake bite patients according to the recommended immunization schedule (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although snake bites may result in the inoculation of bacteria, infection is rare. In a prospective observational study of 53 patients, there were no cases of documented infection following snake bite [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/6\">",
"     6",
"    </a>",
"    ]. Antibiotics (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ) should only be administered for established infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/7\">",
"     7",
"    </a>",
"    ] or for heavily contaminated wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Supportive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of coral snake bites are at high risk for neuromuscular weakness and respiratory failure. Neurotoxicity may also progress despite administration of antivenom [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, all patients warrant frequent, repeated neurologic examination and ancillary assessment of the adequacy of ventilation to facilitate early detection of weakness. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Ancillary studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinician should intervene with endotracheal intubation and mechanical ventilation once signs of respiratory failure develop, regardless of whether they have received antivenom or not. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'North American coral snake antivenom'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NORTH AMERICAN CORAL SNAKE ANTIVENOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antivenom administration is the mainstay for treatment of coral snake bite. A horse serum based antivenom for management of Elapidae bites was previously available for treatment of Eastern or Texas coral snake bites. However, the manufacturer discontinued production of this antivenom in 2006, and all hospital stock is expired as of October 2008. The US Food and Drug Administration has approved an extension of the expiration date until October 31, 2013, but ONLY for lot number 4030026 of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American Coral Snake Antivenom",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a medical toxicologist or other physician with experience in managing coral snake bites is recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222. Outside of the US, the World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American coral snake antivenom",
"    </a>",
"    (lot number 4030026) should be given to patients with any type of neurotoxicity after a suspected Texas or Eastern coral snake bite. In the past, it was recommended to also administer antivenom to asymptomatic patients with a confirmed Texas or Eastern coral snake bite. However, because of the progressive scarcity of the FDA-approved antivenom, the likelihood that additional antivenom will not be available until at least 2013 and in an effort to minimize the unnecessary use of this product, the current recommendation is to wait until systemic symptoms develop to administer antivenom [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients who do not receive antivenom may require endotracheal intubation and mechanical ventilation for up to one week [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American coral snake antivenom",
"    </a>",
"    does",
"    <strong>",
"     not",
"    </strong>",
"    neutralize venoms of the Arizona or Sonoran coral snake. However, clinically significant bites from these snakes have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative contraindications to administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American coral snake antivenom",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Known allergy to horse products or horse serum",
"     </li>",
"     <li>",
"      Prior allergic reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"       North American coral snake antivenom",
"      </a>",
"     </li>",
"     <li>",
"      Inability to manage a potential allergic reaction (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute hypersensitivity reactions'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antivenom administration is potentially associated with severe allergic reactions; it should only occur in a continuously monitored emergency or intensive care unit setting.",
"   </p>",
"   <p>",
"    Although the manufacturer&rsquo;s insert recommends skin testing, it is insufficiently sensitive or specific to determine the risk of allergic reaction. If antivenom is indicated, it should be given without skin testing, and the physician should be prepared to treat allergic reactions, should they occur. &nbsp;",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American coral snake antivenom",
"    </a>",
"    is three to five vials by slow intravenous push. Initial doses up to 10 vials may be necessary to treat small children or patients whose bites were caused by large coral snakes or were associated with prolonged attachment of the snake [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who continue to have progressive signs of weakness after initial treatment with antivenom should receive an additional five vials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"     North American coral snake antivenom",
"    </a>",
"    is derived from horse serum. Allergic reactions and serum sickness are common complications. We advocate the immediate availability of epinephrine (1:1000 preparation 1",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    0.3 to 0.5 mg IM in the anterolateral thigh or 1:10,000 preparation 0.1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for continuous IV infusion titrated to effect),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or similar antihistamine, intravenous corticosteroids, and inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    during antivenom administration. In addition, antivenom should only be given in settings where rapid response to an acute hypersensitivity reaction is possible, such as an emergency department or intensive care unit.",
"   </p>",
"   <p>",
"    The clinician should immediately stop antivenom infusion in patients who experience signs of acute hypersensitivity (eg, anaphylactic shock, oropharyngeal swelling, bronchospasm, urticaria). These patients should receive treatment for anaphylaxis as outlined in the rapid overviews for anaphylaxis in adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 2",
"    </a>",
"    ) and in children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As a proportion of acute hypersensitivity is probably due to nonimmunologic mechanisms, recurrent reactions are not inevitable and the clinician may attempt to resume antivenom. A reassessment of the potential risks and benefits should be made prior to re-administration of antivenom, particularly where severe hypersensitivity reactions have occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment options if approved antivenom is not available",
"    </span>",
"    &nbsp;&mdash;&nbsp;If lot number 4030026 is not available, no data exist concerning the benefits or risks of giving expired antivenom after an Eastern or Texas coral snake bite. Use of expired medications or biological agents in the US is specifically prohibited by the FDA, JCAHO, and by law in some states. In addition, prompt supportive care for respiratory failure, including endotracheal intubation and mechanical ventilation, without antivenom administration, should result in complete recovery in most patients, although duration of mechanical ventilation may be as long as one week [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compassionate release of expired Elapidae antivenom may be an option when the benefits outweigh the risks in an individual patient and only if an adequate supply of lot number 4030026 of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"       North American Coral Snake Antivenom",
"      </a>",
"      is not available. This treatment should only occur after consultation with a regional poison control center and a medical toxicologist. In addition, informed consent should be obtained from the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family. In situations where other expired snake antivenoms have been used, antivenom that appears clear in the vial has been fully effective and opacified antivenom has had decreased potency [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The following antivenoms have been shown to neutralize North American coral snake venoms when given before envenomation in small animal studies [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mexican coral snake antivenom (Coralmyn&reg;)",
"     </li>",
"     <li>",
"      Tiger Snake Antivenom (produced in Australia by CSL, LTD)",
"     </li>",
"     <li>",
"      Anticoral antivenom (produced by Instituto Clodomiro Picado, Costa Rica)",
"      <br/>",
"      <br/>",
"      The ability of these antivenoms to reverse symptoms after North American coral snake envenomation has not been studied. North American zoos that care for exotic snakes may have these antivenoms. A regional poison center (1-800-222-1222) can assist in locating the nearest supplies of foreign antivenom and arranging contact. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       Neostigmine",
"      </a>",
"      has reversed neuromuscular blockade with regression of paralysis in combination with antivenom in victims of Micrurus frontalis envenomation in Brazil [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/16\">",
"       16",
"      </a>",
"      ]. Administration in victims of North American coral snake bite may have similar benefits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have required treatment with antivenom require hospital admission for further observation and supportive care.",
"   </p>",
"   <p>",
"    Asymptomatic patients with a coral snake bite should be observed for 12 to 24 hours because neurotoxicity may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most victims of coral snake bites fully recover, and death is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/775/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RESOURCES FOR INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phone number for the national poisons information hotline, administered by the American Association of Poison Control Centers, is 1-800-222-1222. For clinicians outside of the United States, the World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coral snake (Elapidae) bites are uncommon and rarely result in death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial first aid of envenomation is directed at reducing the spread of venom and expediting transfer to an appropriate medical center. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'First aid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pressure immobilization may be useful for bites by coral snakes, especially when there may be significant delays in transfer to medical facilities (",
"      <a class=\"graphic graphic_figure graphicRef68766 \" href=\"UTD.htm?35/62/36842\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link&amp;anchor=H4#H4\">",
"       \"Principles of snake bite management worldwide\", section on 'Pressure immobilization'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pressure immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic coral snake envenomation causes neurotoxicity, manifesting as muscular weakness or paralysis accompanied by respiratory depression or respiratory failure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the risk of progressive neuromuscular weakness with respiratory failure, victims of coral snake bites should have serial clinical assessment of respiratory muscle strength and may benefit from serial measurement of pulmonary function, noninvasive capnography,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood gas measurement. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with a medical toxicologist or other physician with experience in managing coral snake bites is recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If available,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34708?source=see_link\">",
"       North American coral snake antivenom",
"      </a>",
"      (lot number 4030026) should be given to patients with any type of neurotoxicity after a suspected Texas or Eastern coral snake bite or to patients manifesting other systemic effects. North American coral snake antivenom does",
"      <strong>",
"       not",
"      </strong>",
"      neutralize venoms of the Arizona or Sonoran coral snake. Alternative therapies exist if the FDA-approved coral snake antivenom is not available and expert assistance by a medical toxicologist should be sought (1-800-222-1222). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should immediately stop antivenom infusion in patients who experience signs of acute hypersensitivity (eg, anaphylactic shock, oropharyngeal swelling, bronchospasm, urticaria). These patients should receive treatment for anaphylaxis as outlined in the rapid overviews for anaphylaxis in adults (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"       table 2",
"      </a>",
"      ) and in children (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/1\">",
"      Norris RL, Pfalzgraf RR, Laing G. Death following coral snake bite in the United States--first documented case (with ELISA confirmation of envenomation) in over 40 years. Toxicon 2009; 53:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/2\">",
"      Norris RL, Dart RC. Apparent coral snake envenomation in a patient without visible fang marks. Am J Emerg Med 1989; 7:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/3\">",
"      Walter FG, Bilden EF, Gibly RL. Envenomations. Crit Care Clin 1999; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/4\">",
"      Corbett SW, Anderson B, Nelson B, et al. Most lay people can correctly identify indigenous venomous snakes. Am J Emerg Med 2005; 23:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/5\">",
"      RUSSELL FE, EVENTOV R. LETHALITY OF CRUDE AND LYOPHILIZED CROTALUS VENOM. Toxicon 1964; 15:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/6\">",
"      LoVecchio F, Klemens J, Welch S, Rodriguez R. Antibiotics after rattlesnake envenomation. J Emerg Med 2002; 23:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/7\">",
"      Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/8\">",
"      Kitchens CS, Van Mierop LH. Envenomation by the Eastern coral snake (Micrurus fulvius fulvius). A study of 39 victims. JAMA 1987; 258:1615.",
"     </a>",
"    </li>",
"    <li>",
"     Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot 4030026 Through October 31, 2013 file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm325899.htm (Accessed on November 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/10\">",
"      Lewis-Younger C. Update on the coral snake antivenom shortage. Clin Toxicol 2012; 50:652.",
"     </a>",
"    </li>",
"    <li>",
"     Walter FG, Chase PB, Fernandez MC, McNally J. Venomous snakes. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannow MW, Borron SW, Burns MJ.  (Eds), Saunders, Philadelphia 2007. p.422.",
"    </li>",
"    <li>",
"     Theakston RDG, Lalloo DG. Venomous bites and stings. In: Principles and Practice of Travel Medicine, Zuckerman JN.  (Ed), John Wiley &amp; Sons, West Sussex 2001. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/13\">",
"      Wisniewski MS, Hill RE, Havey JM, et al. Australian tiger snake (Notechis scutatus) and mexican coral snake (Micruris species) antivenoms prevent death from United States coral snake (Micrurus fulvius fulvius) venom in a mouse model. J Toxicol Clin Toxicol 2003; 41:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/14\">",
"      S&aacute;nchez EE, Lopez-Johnston JC, Rodr&iacute;guez-Acosta A, P&eacute;rez JC. Neutralization of two North American coral snake venoms with United States and Mexican antivenoms. Toxicon 2008; 51:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/15\">",
"      Arce V, Rojas E, Ownby CL, et al. Preclinical assessment of the ability of polyvalent (Crotalinae) and anticoral (Elapidae) antivenoms produced in Costa Rica to neutralize the venoms of North American snakes. Toxicon 2003; 41:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/16\">",
"      Vital Brazil O, Vieira RJ. Neostigmine in the treatment of snake accidents caused by Micrurus frontalis: report of two cases (1). Rev Inst Med Trop Sao Paulo 1996; 38:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/775/abstract/17\">",
"      Johnson PN, McGoodwin L, Banner W Jr. Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children. Emerg Med J 2008; 25:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6599 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_775=[""].join("\n");
var outline_f0_48_775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FIRST AID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pressure immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Venomous or nonvenomous?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Techniques to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Supportive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NORTH AMERICAN CORAL SNAKE ANTIVENOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment options if approved antivenom is not available",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RESOURCES FOR INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6599|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/62/36842\" title=\"figure 1\">",
"      First aid snake bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 2\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 3\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_776="Pathogenesis, clinical manifestations, and treatment of late syphilis";
var content_f0_48_776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical manifestations, and treatment of late syphilis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/776/contributors\">",
"     P Frederick Sparling, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/776/contributors\">",
"     Charles B Hicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/776/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/776/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/48/776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is a chronic infection caused by the bacterium Treponema pallidum. During the initial phase of infection, the organism disseminates widely, setting the stage for subsequent manifestations. If untreated, syphilis can have a number of significant late manifestations, including cardiovascular, gummatous, and neurologic complications.",
"   </p>",
"   <p>",
"    The management of syphilis is based on its classification into stages of disease: early syphilis (includes primary, secondary, and early latent syphilis); late or tertiary syphilis (includes cardiovascular and gummatous syphilis); and neurosyphilis (includes central nervous system disease and ocular syphilis) (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of late syphilis will be reviewed here. The epidemiology, pathogenesis, diagnosis, and clinical manifestations of neurosyphilis, the treatment of early syphilis, and the approach to syphilis in the setting of HIV infection or pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late syphilis is somewhat arbitrarily defined as the stages of syphilis that occur after early (primary or secondary) or early latent syphilis. Latent syphilis of uncertain duration is managed as if it were late latent syphilis. Tertiary syphilis is synonymous with late syphilis and refers to symptomatic manifestations of the disease involving the central nervous system (CNS), the cardiovascular system, or the skin and subcutaneous tissues (gummas). Gummas can also involve bone and other tissues. Late syphilis can arise as early as one year after initial infection or up to 25 years or more later. CNS syphilis is the most common presentation of late syphilis observed in current clinical practice. It also is the most difficult to diagnose and treat.",
"   </p>",
"   <p>",
"    Latent syphilis is defined as asymptomatic infection, as determined by a reactive syphilis serology and the absence of signs or symptoms of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Latent syphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE OF LATE SYPHILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late syphilis occurs in an uncertain proportion of patients infected by T. pallidum. Based data collected in the preantibiotic era, the proportion may be as high as 25 to 40 percent of all infected persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncertainty about the frequency of late complications stems from the lack of reliable systems for reporting late stages of the disease. In general, there appear to be fewer cases of late syphilis than would be expected given the resurgence in early syphilis that occurred in the United States in the late 1980s and early 1990s; in 2004, the CDC reported that rates of late and late latent syphilis were relatively unchanged over the preceding five years (ranging from 5.5 to 6.0 cases per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/1\">",
"     1",
"    </a>",
"    ]. It remains to be seen whether an increase in late syphilis may still be noted as a consequence of the upsurge in cases in prior decades.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular immunity is important for control of syphilis in experimental infection and probably contributes to the pathogenesis of late syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/2\">",
"     2",
"    </a>",
"    ]. The prolonged latent period that is characteristic of most types of late syphilis suggests that immune mechanisms may be involved in one of two ways. Waning immunity with aging may facilitate recrudescence of a small number of treponemes that had survived in sequestered sites. Alternatively, a partially immune hypersensitive host may react to the presence of treponemes, engendering a chronic inflammatory response.",
"   </p>",
"   <p>",
"    Gummas, or late benign syphilis often involving the skin, viscera, or other tissues (eg, bone, brain, abdominal viscera), are characterized pathologically by the presence of granulomas, a finding that is consistent with a cellular hypersensitivity reaction. Experimental studies with human subjects who were inoculated cutaneously with small numbers of live T. pallidum showed that gummas developed only in those who had had previous syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/3\">",
"     3",
"    </a>",
"    ]. This suggests that development of gummas requires an immune response insufficient to be protective, but substantial enough to cause tissue damage and granuloma formation in the reinfected host.",
"   </p>",
"   <p>",
"    Small vessel vasculitis is a common manifestation of secondary and later stages of syphilis as evidenced by the presence of lymphocytes and plasma cells infiltrating blood vessels and perivascular tissues. Cardiovascular syphilis with involvement of the ascending arch of the aorta and aortic valve is a consequence of vasculitis of the vasa vasorum (\"endarteritis obliterans\").",
"   </p>",
"   <p>",
"    The pathogenesis of neurosyphilis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of late syphilis are highly variable. The classic descriptions may be altered by antimicrobial therapy administered for other diagnoses in the antibiotic era. In general, a strong index of suspicion is essential to the proper clinical diagnosis of syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gummatous syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gummatous syphilis is very uncommon in the present era. Gummas may occur anywhere, including skin, bones, or internal organs. On the skin, gummas may present as ulcers or heaped up granulomatous lesions with a round, irregular or serpiginous shape. They range from small to very large and may be severe in malnourished individuals (\"rupial\" lesions).",
"   </p>",
"   <p>",
"    Visceral gummas may present as a mass lesion. If a biopsy shows granulomas, lesions may be mistaken for a number of other diseases, including sarcoidosis, that are characterized by granulomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although gummas were exceedingly rare in the penicillin era before the onset of HIV disease, case reports in HIV-infected persons have appeared in the last decade. Most of these have involved internal organs. Gummatous syphilis remains the most uncommon type of late syphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular syphilis classically involves the ascending thoracic aorta resulting in a dilated aorta and aortic valve regurgitation. The onset is typically insidious; most patients present with an asymptomatic murmur or with left heart failure. Clinical manifestations typically occur 15 to 30 years from initial infection in the untreated patient. Syphilitic aneurysms rarely lead to dissection. Syphilis may also involve the coronary arteries, resulting in coronary artery narrowing and thrombosis. The disorder is thought to be a consequence of vasculitis in the vasa vasorum leading to a weakening of the wall of the aortic root [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination may reveal a high-pitched \"tambour\" second sound, but this finding is neither specific nor sensitive. Chest films often show a calcified ascending arch of the aorta, reflecting the chronic inflammation of the intima; this finding is not usually seen in arteriosclerotic disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82736 \" href=\"UTD.htm?9/40/9871\">",
"     image 1",
"    </a>",
"    ). Coronary ostial stenosis may sometimes be found on catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many forms of CNS syphilis, which may occur as early as one year after initial infection to 25 years later. CNS manifestations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of syphilis is based on clinical and laboratory testing. The details of serologic testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of penicillin in treating syphilis is well established, there has never been a conclusive prospective controlled clinical trial of the dose or duration of therapy in various stages of disease. The current recommendations are based on what is known about the pharmacokinetics of the available drugs, the effect on T. pallidum in vitro, and more than 50 years of clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of syphilis requires a prolonged duration of antimicrobial therapy, since T. pallidum divides slowly, averaging one doubling in vivo per day [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/3\">",
"     3",
"    </a>",
"    ]. A persistent level &gt;0.03",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of penicillin is needed in blood to ensure killing of T. pallidum; increasing the dose does not clear treponemes more quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/7\">",
"     7",
"    </a>",
"    ]. Long-acting depot penicillin preparations have proven very successful in the treatment of early and late stages of syphilis. Benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2.4 million units IM once weekly for three weeks) provides low but persistent serum levels of penicillin, and is standard therapy for late (tertiary) syphilis (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. While it has the advantage of not requiring daily patient adherence to taking the medication, it does require patients to follow-up consistently over the three week span of treatment to receive the full course of therapy.",
"   </p>",
"   <p>",
"    In contrast, neurosyphilis, which is considered late syphilis, requires intravenous therapy with penicillin. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Neurosyphilis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Late (tertiary) syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with gummatous or cardiovascular syphilis should have a cerebrospinal fluid (CSF) examination prior to initiation of therapy to assess for neurosyphilis. The specifics of the diagnosis of neurosyphilis in this setting are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gummas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2.4 million units IM) once weekly for three weeks is the recommended treatment regimen for gummatous syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6\">",
"     6",
"    </a>",
"    ]. Cutaneous gummas usually heal rapidly after penicillin therapy with little scarring.",
"   </p>",
"   <p>",
"    Patients allergic to penicillin may be treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg PO BID for 28 days) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g IV or IM daily for 10 to 14 days), although there are few data on the efficacy of these regimens in late syphilis (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Intravenous administration is favored over intramuscular injections of ceftriaxone, which are painful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular syphilis can be treated with benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2.4 million units IM once weekly for three weeks). However, some specialists prefer to treat cardiovascular syphilis with the same regimen as for neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Neurosyphilis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antibiotic therapy does not reverse the cardiovascular manifestations of syphilis, but it may halt progression of disease. Involvement of the coronary arteries may result in coronary thrombosis immediately following therapy, leading some authorities to recommend corticosteroids at the time of treatment. However, there is no consensus and little evidence regarding the efficacy of this adjunctive therapy in preventing complications, and we do not recommend the use of steroids in this setting.",
"   </p>",
"   <p>",
"    Patients with an uncertain history of penicillin allergy, or those whose allergic manifestations are limited to mild rash, may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 g IV or IM daily for 10 to 14 days. Patients with a history of severe beta lactam reactions, including anaphylaxis, should either be desensitized or treated with a non-beta lactam regimen. There are few data on efficacy of alternative regimens (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the 1950s suggested that long-acting depot penicillin therapy of early syphilis prevented the subsequent development of late syphilis, including neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, two observations have led to revisions in treatment recommendations for neurosyphilis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is well known that recommended doses of benzathine penicillin do not produce measurable CSF levels of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several case reports of HIV-infected patients treated with benzathine penicillin who subsequently developed symptomatic neurosyphilis have been published; in some instances, viable T. pallidum were demonstrated in CSF after therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/8,9,14,15\">",
"       8,9,14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intravenous penicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (3 to 4 million units IV Q 4h or 18 to 24 million units per day by continuous infusion for 10 to 14 days) is the drug of choice for neurosyphilis, as recommended by the Centers for Disease Control and Prevention (CDC) (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. This treatment may require initial hospitalization, although newer administration systems using portable constant infusion pumps permit outpatient intravenous penicillin therapy in many instances.",
"   </p>",
"   <p>",
"    The same regimen recommended for neurosyphilis should be administered to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with syphilitic uveitis or other ocular manifestations of syphilis.",
"     </li>",
"     <li>",
"      Patients with auditory disease secondary to syphilis",
"     </li>",
"     <li>",
"      Patients strongly suspected of having late CNS syphilis (eg, compatible clinical syndrome, positive blood serology, and CSF pleocytosis with a non-reactive CSF VDRL). In HIV-infected persons, an RPR or VDRL titer of &gt;1:32 is strongly suggestive of CNS syphilis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link&amp;anchor=H15#H15\">",
"       \"Neurosyphilis\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"       \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted in the CDC guidelines, the overall duration of treatment for neurosyphilis is shorter (10 to 14 days) than the regimens used for late syphilis (three weeks). Some specialists administer benzathine penicillin 2.4 million units IM once per week for three weeks after completion of the neurosyphilis regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6\">",
"     6",
"    </a>",
"    ]. Others suggest one additional dose of benzathine for the possibility of coexisting latent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/12\">",
"     12",
"    </a>",
"    ]. The most cautious approach would be the use of three additional doses of benzathine penicillin following intravenous therapy. While the pathophysiology of the organism and the overall safety of the drug make this treatment plan reasonable, it may be challenging to get patient follow-up for the full course of therapy; there are no clinical trial data to make any firm recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Procaine penicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If compliance can be ensured, procaine penicillin (2.4 million units IM once daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    (500 mg orally four times a day) for 10 to 14 days is an outpatient option recommended by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinicians should be aware that probenecid is contraindicated in patients with sulfonamide allergy.",
"   </p>",
"   <p>",
"    This combination provides higher serum levels than benzathine penicillin; however, CSF levels often are not detectable and this regimen has not been well studied for the treatment of neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/16\">",
"     16",
"    </a>",
"    ]. IM procaine penicillin also can be painful and patient willingness to complete the full course of therapy is variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (3 grams twice daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    (0.5 to 1 gram orally) for 14 days or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg orally twice daily) for 21 days. These regimens are not recommended by the CDC and are not considered standard-of-care. Their use should be reserved for exceptional circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances it may be reasonable to administer benzathine penicillin (2.4 million units IM weekly for three weeks) as outpatient therapy for selected HIV-negative patients who have reactive serum syphilis serologic tests and nonspecific symptoms that may suggest the possibility of mild neurosyphilis (eg, elderly patients with mild cognitive deficits consistent with early dementia). In such patients, the risk and inconvenience of sampling CSF may exceed the very unlikely prospect of future consequences from under-treated neurosyphilis. Clinical judgment and individualization of the management strategy for each specific situation is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13263108\">",
"    <span class=\"h1\">",
"     HOST-SPECIFIC TREATMENT CONCERNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patients with a history of penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who report a history of severe allergic reaction to penicillin may remain allergic their entire lives while others may stop expressing penicillin-specific IgE. These latter individuals may be safely treated with penicillin. Penicillin skin testing with the major and minor determinants of penicillin can reliably identify persons at high risk for penicillin reactions. The use of such testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with neurosyphilis who are allergic to penicillin should undergo penicillin desensitization, since this is clearly the optimal treatment for CNS infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6,10,16\">",
"     6,10,16",
"    </a>",
"    ]. Patients should generally be desensitized in a hospital setting in consultation with an allergist. Non-penicillin regimens are not recommended for patients with documented neurosyphilis.",
"   </p>",
"   <p>",
"    The health care provider should inform the patient who undergoes desensitization that the tolerance induced persists only as long as the patient continues to receive the drug. Once antibiotic therapy is stopped for a period of more than 24 hours, repeat desensitization is required if penicillin is to be used again. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative approach in patients with relatively mild manifestations of penicillin allergy is to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    IV or IM (2 grams daily for 10 to 14 days), although the possibility of cross-reactivity (approximately 5 percent) still exists. If this option is selected, careful clinical and serologic follow-up in consultation with an infectious disease specialist is recommended since there is little clinical data on this approach and relapses have been documented (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. Patient monitoring is discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Patient monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong association between syphilis and HIV infection, at least in part due to the fact that both are sexually transmitted diseases (STDs). The treatment of late syphilis in the HIV-infected patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is of particular concern during pregnancy because of the risk of transplacental infection of the fetus. Congenital infection is associated with several adverse outcomes including premature delivery, low birth weight, and congenital anomalies. The treatment of syphilis in pregnant women is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since T. pallidum cannot be cultured in the laboratory, the success of treatment must be inferred through indirect measures, such as serologic monitoring of nontreponemal (VDRL or RPR) titers. Patients treated for late syphilis or neurosyphilis should have serum nontreponemal titers measured at three and six months followed thereafter at six-month intervals for up to two years or until the serology reverts to nonreactive. Titers should fall fourfold within a year, and then continue to fall thereafter, although there is considerable variability in the serologic response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Late (tertiary) syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical changes associated with late cardiovascular and noncutaneous gummatous syphilis are not likely to be significantly improved by treatment. Treatment generally prevents further progression of disease. Follow up should include assessment of serologic tests as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat neurologic examinations with CSF analysis is recommended by the CDC every six months until the cell count has normalized; changes in CSF VDRL and protein concentrations are slower to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/776/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Indications for retreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients do not respond to initial treatment regimens, as evidenced by failure of nontreponemal serum titers to decrease at least fourfold over 6 to 12 months of follow-up. Failure to achieve an acceptable serologic response may be a consequence of reinfection or relapse. It can be very difficult to distinguish one from the other clinically. Since drug resistance to penicillin has not been described, most cases are attributed to reinfection, although some likely represent a slow decay in the nontreponemal titer rather than recurrent infection. In a patient with neurosyphilis, failure of the CSF cell count to decrease in the first six months or lack of resolution of CSF pleocytosis after two years should prompt retreatment.",
"   </p>",
"   <p>",
"    Patients believed to have failed initial therapy for gummatous or cardiovascular syphilis are managed by administering another course of benzathine penicillin, and ensuring that all sexual contacts have also been adequately treated. Retreatment of neurosyphilis usually requires 14 days of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    . There is no evidence that longer courses of treatment or use of different antibiotics changes the outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION AND SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no vaccine for syphilis. Safer sex practices are essential for the prevention of infection. Contact tracing and treatment of sexual contacts of patients with infectious syphilis has been highly effective in limiting the further spread of the disease in communities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with HIV infection should be tested for syphilis, and all patients with syphilis should be tested for HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"       \"Patient information: Syphilis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of late syphilis are protean and a high index of suspicion is necessary for proper diagnosis. Gummatous syphilis can involve any part of the body including the skin, bones, or internal organs. On the skin, gummas may appear as ulcerative lesions; in internal organs, they are more likely to may appear as a mass. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular syphilis most commonly involves the aortic root, resulting in aortic insufficiency. Coronary artery involvement can lead to thrombosis and myocardial infarction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurosyphilis can involve the meninges, brain, or spinal cord and may present in a wide range of ways, including meningitis, general paresis, tabes dorsalis, or meningovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"       \"Neurosyphilis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with late syphilis who are not allergic, we recommend treatment with penicillin (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We recommend the standard regimens as per the CDC STD Treatment Guidelines:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gummatous and cardiovascular syphilis: Benzathine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (2.4 million units IM once weekly) for three weeks. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late (tertiary) syphilis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neurosyphilis:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      (18 to 24 million units per day, administered as 3 to 4 million units IV every four hours or continuous infusion) for 10 to 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with late syphilis who are penicillin allergic, we recommend the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gummatous syphilis:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      100 mg twice daily for 28 days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiovascular syphilis:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (1 g daily for 10 to 14 days) in patients with history of mild penicillin allergy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurosyphilis: Patients with neurosyphilis who have a serious penicillin allergy (eg, anaphylaxis), should undergo desensitization to beta-lactams, as recommended by the CDC STD Treatment Guidelines. This should be done in consultation with an experienced allergist. After desensitization,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      should be initiated (18 to 24 million units per day, administered as 3 to 4 million units IV every four hours or continuous infusion) for 10 to 14 days (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In patients with mild penicillin allergies, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV daily) for 10 to 14 days with careful observation for cross-reactivity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once therapy has been completed, the serum nontreponemal (VDRL or RPR) titers should be monitored after three and six months and then every six months thereafter for two years. If the titer does not fall by two dilutions (fourfold) six months following treatment, then retreatment should be considered with a second course of therapy appropriate to the diagnosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with neurosyphilis, CSF parameters should be monitored every six months until the pleocytosis has resolved. If the pleocytosis does not improve by six months, or the CSF profile has not normalized within two years, we suggest a second course of therapy for neurosyphilis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2004. Atlanta GA: U.S. Department of Health and Human Services, September 2005.",
"    </li>",
"    <li>",
"     Wicher, K, et al. Immunopathology of syphilis. In: Pathogenesis and Immunology of Treponemal Infection, Schell, RF, et al (Eds), Marcel Dekker, New York, NY 1983. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/3\">",
"      MAGNUSON HJ, THOMAS EW, OLANSKY S, et al. Inoculation syphilis in human volunteers. Medicine (Baltimore) 1956; 35:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/4\">",
"      Kennedy JL, Barnard JJ, Prahlow JA. Syphilitic coronary artery ostial stenosis resulting in acute myocardial infarction and death. Cardiology 2006; 105:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/5\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1998. A 46-year-old man with chest pain and coronary ostial stenosis. N Engl J Med 1998; 338:897.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/7\">",
"      Tramont EC. Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA 1976; 236:2206.",
"     </a>",
"    </li>",
"    <li>",
"     Swartz, MN, Healy, BP, Musher, DM. Late Syphilis. In: Sexually Transmitted Diseases, Holmes, KK, Sparling, PF, Mardh, PA, et al (Eds), McGraw Hill, New York, NY 1999. p.487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/9\">",
"      Scheck DN, Hook EW 3rd. Neurosyphilis. Infect Dis Clin North Am 1994; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/10\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/11\">",
"      Hook EW 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med 1992; 326:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/12\">",
"      Augenbraun MH. Treatment of syphilis 2001: nonpregnant adults. Clin Infect Dis 2002; 35:S187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/13\">",
"      Polnikorn N, Witoonpanich R, Vorachit M, et al. Penicillin concentrations in cerebrospinal fluid after different treatment regimens for syphilis. Br J Vener Dis 1980; 56:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/14\">",
"      Gordon SM, Eaton ME, George R, et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. N Engl J Med 1994; 331:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/15\">",
"      Walter T, Lebouche B, Miailhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis 2006; 43:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/16\">",
"      van der Valk PG, Kraai EJ, van Voorst Vader PC, et al. Penicillin concentrations in cerebrospinal fluid (CSF) during repository treatment regimen for syphilis. Genitourin Med 1988; 64:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/776/abstract/17\">",
"      Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004; 38:1001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7597 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_776=[""].join("\n");
var outline_f0_48_776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE OF LATE SYPHILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gummatous syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Late (tertiary) syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gummas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intravenous penicillin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Procaine penicillin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other alternatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13263108\">",
"      HOST-SPECIFIC TREATMENT CONCERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patients with a history of penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Late (tertiary) syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Indications for retreatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7597|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/40/9871\" title=\"diagnostic image 1\">",
"      Syphilitic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/1/26652\" title=\"table 1\">",
"      Rx syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=related_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_777="Quinidine: Drug information";
var content_f0_48_777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/17/23829?source=see_link\">",
"    see \"Quinidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"    see \"Quinidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinidine&reg;;",
"     </li>",
"     <li>",
"      BioQuin&reg; Durules&trade;;",
"     </li>",
"     <li>",
"      Novo-Quinidin;",
"     </li>",
"     <li>",
"      Quinate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ia;",
"     </li>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of the salt: 267 mg of quinidine gluconate = 200 mg of quinidine sulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Antiarrhythmic:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release formulations:",
"     </i>",
"     Quinidine sulfate: Initial: 200-400 mg/dose every 6 hours the dose may be increased cautiously to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Quinidine sulfate: Initial: 300 mg every 8-12 hours; the dose may be increased cautiously to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Quinidine gluconate: Initial: 324 mg every 8-12 hours; the dose may be increased cautiously to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Severe malaria, treatment:",
"     </b>",
"     I.V. (quinidine gluconate): 10 mg/kg infused over 60-120 minutes followed by  0.02 mg/kg/minute continuous infusion for &ge;24 hours; alternatively, may administer 24 mg/kg loading dose over 4 hours, followed by 12 mg/kg over 4 hours every 8 hours (beginning 8 hours after initiation of the loading dose); complete treatment with oral quinine once parasite density &lt;1% and patient can receive oral medication; total duration of treatment (quinidine/quinine): 3 days (Africa or South America) or 7 days (Southeast Asia); use in combination with doxycycline, tetracycline or clindamycin (CDC malaria guidelines, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Close monitoring, including telemetry, required.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"      see \"Quinidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of the salt: 267 mg of quinidine gluconate = 200 mg of quinidine sulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Severe malaria, treatment:",
"     </b>",
"     Children: I.V. (quinidine gluconate): 10 mg/kg infused over 60-120 minutes followed by  0.02 mg/kg/minute continuous infusion for &ge;24 hours; alternatively, may administer 24 mg/kg loading dose over 4 hours, followed by 12 mg/kg over 4 hours every 8 hours (beginning 8 hours after initiation of the loading dose); complete treatment with oral quinine once parasite density &lt;1% and patient can receive oral medication; total duration of treatment (quinidine/quinine): 3 days (Africa or South America) or 7 days (Southeast Asia); use in combination with doxycycline, tetracycline or clindamycin (CDC malaria guidelines, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Close monitoring, including telemetry, required.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling recommends that caution should be used in patients with renal impairment; however, no specific dosage adjustment guidelines are available. The following guidelines have been used by some clinicians (Aronoff, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dose following hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CRRT: No dosage adjustment required; monitor serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; hepatic impairment decreases clearance; dosage adjustments are not provided in the manufacturers&rsquo; labeling although toxicity may occur if the dose is not appropriately adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as gluconate: 80 mg/mL (10 mL) [equivalent to quinidine base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 200 mg [equivalent to quinidine base 166 mg], 300 mg [equivalent to quinidine base 249 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as gluconate: 324 mg [equivalent to quinidine base 202 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sulfate: 300 mg [equivalent to quinidine base 249 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not crush, chew, or break sustained release dosage forms. Some preparations of quinidine gluconate extended release tablets may be split in half to facilitate dosage titration; tablets are not scored.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Minimize use of PVC tubing to enhance bioavailability; shorter tubing lengths are recommended by the manufacturer",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     Quinidine gluconate: 800 mg in 50 mL (concentration: 16 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F216528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diazepam, milrinone, nesiritide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Quinidine gluconate and sulfate salts:",
"     </i>",
"     Conversion and prevention of relapse into atrial fibrillation and/or flutter; suppression of ventricular arrhythmias.",
"     <b>",
"      Note:",
"     </b>",
"     Due to proarrhythmic effects, use should be reserved for life-threatening arrhythmias. Moreover, the use of quinidine has largely been replaced by more effective/safer antiarrhythmic agents and/or nonpharmacologic therapies (eg, radiofrequency ablation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Quinidine gluconate (I.V. formulation):",
"     </i>",
"     Conversion of atrial fibrillation/flutter and ventricular tachycardia.",
"     <b>",
"      Note:",
"     </b>",
"     The use of I.V. quinidine gluconate for these indications has been replaced by more effective/safer antiarrhythmic agents (eg, amiodarone and procainamide).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Quinidine gluconate (I.V. formulation) and quinidine sulfate:",
"     </i>",
"     Treatment of malaria (",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7789583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paroxysmal supraventricular tachycardia, paroxysmal AV junctional rhythm, and symptomatic atrial or ventricular premature contractions; short QT syndrome; Brugada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       QuiNIDine may be confused with cloNIDine, quiNINE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (modest prolongation is common, however, excessive prolongation is rare and indicates toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lightheadedness (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (35%), upper GI distress, bitter taste, diarrhea, anorexia, nausea, vomiting, stomach cramping (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina (6%), palpitation (7%), new or worsened arrhythmia (proarrhythmic effect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Syncope (1% to 8%), headache (7%), fatigue (7%), sleep disturbance (3%), tremor (2%), nervousness (2%), incoordination (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal pigmentation, acute psychotic reactions, agranulocytosis, angioedema, arthralgia, bronchospasm, cerebral hypoperfusion (possibly resulting in ataxia, apprehension, and seizure), cholestasis, confusion, delirium, depression, drug-induced lupus-like syndrome, eczematous dermatitis, esophagitis, exacerbated bradycardia (in sick sinus syndrome), exfoliative rash, fever, flushing, granulomatous hepatitis, hallucinations, heart block, hemolytic anemia, hepatotoxic reaction (rare), hearing impaired, CPK increased, lichen planus, livedo reticularis, lymphadenopathy, melanin pigmentation of the hard palate, myalgia, mydriasis, nephropathy, optic neuritis, pancytopenia, paradoxical increase in ventricular rate during atrial fibrillation/flutter, photosensitivity, pneumonitis, pruritus, psoriaform rash, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (excessive), respiratory depression, sicca syndrome, tachycardia, thrombocytopenia, thrombocytopenic purpura, torsade de pointes, urticaria, uveitis, vascular collapse, vasculitis, ventricular fibrillation, ventricular tachycardia, vertigo, visual field loss",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cinchonism, a syndrome which may include tinnitus, high-frequency hearing loss, deafness, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium has been associated with quinidine use. Usually associated with chronic toxicity, this syndrome has also been described after brief exposure to a moderate dose in sensitive patients. Vomiting and diarrhea may also occur as isolated reactions to therapeutic quinidine levels.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinidine or any component of the formulation; thrombocytopenia; thrombocytopenic purpura; myasthenia gravis; heart block greater than first degree; idioventricular conduction delays (except in patients with a functioning artificial pacemaker); those adversely affected by anticholinergic activity; concurrent use of quinolone antibiotics which prolong QT interval, cisapride, amprenavir, or ritonavir",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Has been associated with severe hepatotoxic reactions, including granulomatous hepatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: With use, hypersensitivity reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Watch for proarrhythmic effects; may cause QT prolongation and subsequent torsade de pointes. Monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Avoid use in patients with diagnosed or suspected congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Antiarrhythmic drugs have not been shown to enhance survival  in non-life-threatening ventricular arrhythmias and may increase mortality; the risk is greatest with structural heart disease. Quinidine may increase mortality in treatment of atrial fibrillation/flutter.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation/flutter: May increase ventricular response rate in patients with atrial fibrillation or flutter; control AV conduction before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Use with caution in patients at risk for heart block; can unmask sick sinus syndrome (causes bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolysis may occur in patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF; may precipitate or exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduced dosage recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiarrhythmics:  Use with caution with concurrent use of other antiarrhythmics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Use may cause digoxin-induced toxicity; adjust digoxin's dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Different salts: Do not interchange the different salt products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (strong), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of QuiNIDine. Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: QuiNIDine may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Felodipine; Nisoldipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: QuiNIDine may increase the serum concentration of Cardiac Glycosides.  Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of QuiNIDine. Management: Consider alternatives to cimetidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: QuiNIDine may increase the serum concentration of Dabigatran Etexilate.  Management: Canadian (but not U.S.) prescribing information recommends dosing dabigatran 2 hours prior to quinidine, and limiting dabigatran VTE prevention dose post hip/knee replacement to 150 mg/day in patients receiving quinidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: QuiNIDine may increase the serum concentration of Dalfampridine.  Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and quinidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: QuiNIDine may increase the serum concentration of Dextromethorphan.  Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydrocodeine: QuiNIDine may diminish the analgesic effect of Dihydrocodeine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrocodone: QuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of QuiNIDine. Management: Consider separating doses of kaolin and quinidine by at least 2 hours in order to reduce the risk of interaction. Monitor for decreased therapeutic effects of quinidine if kaolin is simultaneously coadministered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of QuiNIDine. Management: Consider alternatives to quinidine in patients with acute lurasidone overdose.  If quinidine treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: QuiNIDine may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine. Management: Avoid quinidine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: QuiNIDine may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: QuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of QuiNIDine. Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline; Vilazodone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine. Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): QuiNIDine may enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Changes in dietary salt intake may alter the rate and extent of quinidine absorption. Quinidine serum levels may be increased if taken with food. Food has a variable effect on absorption of sustained release formulation. The rate of absorption of quinidine may be decreased following the ingestion of grapefruit juice. Excessive intake of fruit juice or vitamin C may decrease urine pH and result in increased clearance of quinidine with decreased serum concentration. Alkaline foods may result in increased quinidine serum concentrations. Management: Avoid changes in dietary salt intake. Grapefruit juice should be avoided. Take around-the-clock to avoid variation in serum levels and with food or milk to avoid GI irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease quinidine levels. Ephedra may worsen arrhythmia. Management: Avoid St John's wort and ephedra.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Quinidine crosses the placenta and can be detected in the amniotic fluid, cord blood, and neonatal serum. Quinidine is indicated for use in the treatment of severe malaria infection in pregnant women (CDC, 2011; Smereck, 2011) and has also been used to treat arrhythmias in pregnancy when other agents are ineffective (European Society of Cardiology, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F216486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or milk to decrease gastrointestinal irritation. Avoid changes in dietary salt intake.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (QuiNIDine Gluconate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (10 mL): $21.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (QuiNIDine Gluconate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 mg (100): $136.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (QuiNIDine Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $105.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (QuiNIDine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $20.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $38.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac monitor required during I.V. administration; CBC, liver and renal function tests, should be routinely performed during long-term administration",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F216476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 2-5 mcg/mL (SI: 6.2-15.4 micromole/L). Patient-dependent therapeutic response occurs at levels of 3-6 mcg/mL (SI: 9.2-18.5 micromole/L). Optimal therapeutic level is method dependent; &gt;6 mcg/mL (SI: &gt;18 micromole/L).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cardioquina (UY);",
"     </li>",
"     <li>",
"      Cardioquinol (EC);",
"     </li>",
"     <li>",
"      Chinidin (BG);",
"     </li>",
"     <li>",
"      Chinidin Retard (HN);",
"     </li>",
"     <li>",
"      Chinidinum prolongatum (PL);",
"     </li>",
"     <li>",
"      Chinidinum sulfuricum (PL);",
"     </li>",
"     <li>",
"      Kiditard (NL);",
"     </li>",
"     <li>",
"      Kinidin (AE, BH, CY, CZ, EG, FI, GR, IE, IQ, IR, JO, KW, LB, LY, NO, OM, PH, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Kinidin Durules (AU);",
"     </li>",
"     <li>",
"      Kinidin durules (PL);",
"     </li>",
"     <li>",
"      Kinidine (NL);",
"     </li>",
"     <li>",
"      Kinilentin (PL);",
"     </li>",
"     <li>",
"      Kinitard (PL);",
"     </li>",
"     <li>",
"      Naticardina (IT);",
"     </li>",
"     <li>",
"      Quinaglute Dura-tabs (ZA);",
"     </li>",
"     <li>",
"      Quinicardine (PE);",
"     </li>",
"     <li>",
"      Quiniduran (IL);",
"     </li>",
"     <li>",
"      Ritmocor (IT);",
"     </li>",
"     <li>",
"      Sulfas-Chinidin (ID);",
"     </li>",
"     <li>",
"      Wanidine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class Ia antiarrhythmic agent; depresses phase O of the action potential; decreases myocardial excitability and conduction velocity, and myocardial contractility by decreasing sodium influx during depolarization and potassium efflux in repolarization; also reduces calcium transport across cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2-3 L/kg, decreased with congestive heart failure (0.5 L/kg), malaria; increased with cirrhosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Newborns: 50% to 70%; Adults: 80% to 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Binds mainly to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein and to a lesser extent albumin; protein-binding changes may occur in  periods of stress due to increased alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein concentrations (eg, acute myocardial infarction) or in certain disease states due to decreased alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein concentrations (eg, cirrhosis,hyperthyroidism, malnutrition)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (50% to 90%) to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Sulfate: ~70% with wide variability between patients (45% to 100%); Gluconate: 70% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma: Children: 3-4 hours; Adults: 6-8 hours; prolonged with elderly, cirrhosis, and congestive heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Sulfate: 2 hours; Gluconate: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (15% to 25% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belhassen B, Glick A, and Viskin S, &ldquo;Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(13):1731-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/15381640/pubmed\" id=\"15381640\" target=\"_blank\">",
"        15381640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coplen SE, Antman EM, Berlin JA, et al, &ldquo;Efficacy and Safety of Quinidine Therapy for Maintenance of Sinus Rhythm After Cardioversion. A Meta-analysis of Randomized Control Trials,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 82:1106-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/2144796/pubmed\" id=\"2144796\" target=\"_blank\">",
"        2144796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(12):781-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/1900101/pubmed\" id=\"1900101\" target=\"_blank\">",
"        1900101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Society for Cardiology, Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology, \"Expert Consensus Document on Management of Cardiovascular Diseases During Pregnancy,\"",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2003, 24(8):761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/12800857/pubmed\" id=\"12800857\" target=\"_blank\">",
"        12800857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaker GC, Blackshear JL, McBride R, et al, &ldquo;Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 20:527-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/1512329/pubmed\" id=\"1512329\" target=\"_blank\">",
"        1512329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morganroth J and Goin JE, &ldquo;Quinidine-Related Mortality in the Short-to-Medium Term Treatment of Ventricular Arrhythmias. A Meta-analysis,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1991, 84(5):1977-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/1834365/pubmed\" id=\"1834365\" target=\"_blank\">",
"        1834365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oberg KC, O'Toole MF, Gallastegui JL, et al, &ldquo;'Late' Proarrhythmia Due to Quinidine,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1994, 74(2):192-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/8023791/pubmed\" id=\"8023791\" target=\"_blank\">",
"        8023791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smereck J, \"Malaria in Pregnancy: Update on Emergency Management,\"",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2011, 40(4):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/20566259/pubmed\" id=\"20566259\" target=\"_blank\">",
"        20566259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolpert C, Schimpf R, Veltmann C, et al, &ldquo;Clinical Characteristics and Treatment of Short QT Syndrome,&rdquo;",
"      <i>",
"       Exp Rev Cardiovasc Ther",
"      </i>",
"      , 2005, 3(4):611-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(5):247-346.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/48/777/abstract-text/16949478 /pubmed\" id=\"16949478 \" target=\"_blank\">",
"        16949478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9846 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_777=[""].join("\n");
var outline_f0_48_777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709382\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216522\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216502\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216515\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216503\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216504\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216505\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216460\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216480\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473101\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216479\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7789583\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216530\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216520\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216484\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216464\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216517\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216469\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216495\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216471\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386486\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216510\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216486\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524699\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216473\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216476\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038793\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216463\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216483\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/17/23829?source=related_link\">",
"      Quinidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=related_link\">",
"      Quinidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_778="Neuromuscular manifestations of systemic sclerosis (scleroderma)";
var content_f0_48_778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuromuscular manifestations of systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/778/contributors\">",
"     Monica L Piecyk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/778/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/778/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/48/778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/48/778/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/48/778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature addressing neurologic involvement in systemic sclerosis (SSc; scleroderma) principally consists of case series and case reports. It includes the following categories, listed in approximate order of frequency:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cranial, entrapment, peripheral, cutaneous, autonomic neuropathies",
"     </li>",
"     <li>",
"      Myopathy",
"     </li>",
"     <li>",
"      Central nervous system involvement, including headache, seizures, stroke, vascular disease, radiculopathy, and myelopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, however, central nervous system (CNS) involvement due to SSc is rare, but complications of other organ damage may have neurologic manifestations. Examples include renal failure, uncontrolled hypertension, and heart or respiratory failure.",
"   </p>",
"   <p>",
"    Estimates of the frequency of neurologic involvement in patients with SSc vary widely, ranging from 0 to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Various forms of neurologic dysfunction have been described in association with diffuse, limited, and linear scleroderma. As an example, linear scleroderma en coup de sabre, which is characterized by a localized band of induration near the forehead, is occasionally associated with neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; focal cerebral abnormalities, seizures, and stroke have also been described in affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased risk of neurologic involvement may be associated with the presence of anti-Scl-70 (anti-topoisomerase-I) and anti-U1-RNP; these antibodies are frequently found in patients with diffuse SSc and overlap syndromes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"     \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"    </a>",
"    .) However, it appears unlikely that these autoantibodies are directly involved in the pathogenesis of neurologic injury.",
"   </p>",
"   <p>",
"    In this topic review, the neurologic disorders that have been described in association with diffuse and limited forms of SSc are presented.",
"   </p>",
"   <p>",
"    Neurologic disease in patients with SSc resulting from the consequences of hypertension, uremia, or pulmonary disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease of the cranial and peripheral nerves and isolated cutaneous sensory branches have been described in association with SSc. It is unknown whether neuropathy in patients with SSc is a primary or secondary event. Possible mechanisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular-dependent neuropathy, which is due to vasculitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vessel wall deterioration of the vasa nervorum",
"     </li>",
"     <li>",
"      Compression-dependent neuropathy, resulting from compression due to edema or fibrosis. This causes progressive demyelination.",
"     </li>",
"     <li>",
"      Autoimmune-dependent neuropathy (antineuronal antibodies) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. However, antibodies directed against a component of myelin do not correlate with peripheral neuropathy in patients with SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRANIAL NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cranial neuropathies have been described in patients with SSc. The most commonly involved is the trigeminal nerve, with dysfunction of the optic, oculomotor, trochlear, abducens, facial, glossopharyngeal, and auditory nerves also being reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/3-6,8,13,17-26\">",
"     3-6,8,13,17-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trigeminal neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigeminal neuropathy is the most common cranial nerve manifestation. In one series of 442 patients with SSc, trigeminal neuropathy occurred in 4 percent and was observed most frequently in those with clinical features of the mixed connective tissue disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    .) It may be the initial SSc manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/19,20,27-30\">",
"     19,20,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying pathophysiology of trigeminal neuropathy in SSc patients is unknown. Electrophysiologic studies suggest that the site of disease is the gasserian ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,31\">",
"     8,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical manifestations and findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms include slowly progressive unilateral or bilateral facial numbness, frequently with associated pain (50 percent of patients) and paresthesia (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,17,18,22,24,32\">",
"     8,17,18,22,24,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .) The pain is usually burning in quality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/22\">",
"     22",
"    </a>",
"    ]. Numbness is most common in the mandibular or maxillary divisions of the nerve, with symptoms in the cheek or around the mouth; the maximal deficit is usually reached after 6 to 24 months. Trigeminal motor function (muscles of mastication) usually is not affected.",
"   </p>",
"   <p>",
"    Sensory loss is present upon physical examination. The corneal reflex is sometimes depressed or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of isolated facial numbness is broad. It includes neuropathy associated with diabetes mellitus, sinus disease, multiple sclerosis, trauma, vertebrobasilar ischemia, and tumors of the brainstem, cerebellopontine angle, skull base, and nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of glucocorticoids is probably not beneficial. In one series of 38 patients with connective tissue diseases (including some with SSc) and trigeminal neuropathy who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , pain improved in two individuals, but facial numbness was unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/22\">",
"     22",
"    </a>",
"    ]. Chronic pain may require the use of analgesics, antidepressants,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticonvulsant medications, as utilized in a manner similar to that for patients with chronic neuropathic pain due to other etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other cranial neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, sensory or motor deficits may occur with involvement of cranial nerves other than the trigeminal nerve. These include facial palsy, glossopharyngeal neuropathy, audiovestibular impairment, and optic neuropathy or neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/5,6,8,19,33-38\">",
"     5,6,8,19,33-38",
"    </a>",
"    ]. In addition, impaired extraocular muscle function may occur due to inflammatory ocular myopathy, restrictive ophthalmopathy, or cranial nerve IV or VI paresis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,19,39-42\">",
"     8,19,39-42",
"    </a>",
"    ]. There is no evidence that any specific treatment is effective for these disorders in patients with SSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ENTRAPMENT NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common of the entrapment neuropathies is compression of the median nerve at the wrist or carpal tunnel syndrome. Nerves at other sites are less frequently involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the frequency of carpal tunnel syndrome (CTS) in patients with SSc vary from less than 5 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/3,4,21,43-45\">",
"     3,4,21,43-45",
"    </a>",
"    ]. CTS sometimes presents prior to the diagnosis of limited [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/46\">",
"     46",
"    </a>",
"    ] or diffuse SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/44,46-50\">",
"     44,46-50",
"    </a>",
"    ]. The most likely pathologic mechanism is fibrosis leading to nerve entrapment. Rarely, calcific deposits may cause focal nerve compression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of the patient with SSc and CTS are similar to those of the individual with the syndrome but without SSc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other compressive neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar neuropathy, posterior tibial neuropathy (tarsal tunnel syndrome), ilioinguinal nerve entrapment, and meralgia paresthetica also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,43-45,51,54,55\">",
"     4,43-45,51,54,55",
"    </a>",
"    ]. Asymptomatic electrodiagnostic evidence of compression neuropathies may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/5,43,45,56\">",
"     5,43,45,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PERIPHERAL POLYNEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral polyneuropathies, consisting of sensory, mixed sensory and motor, and mononeuritis multiplex, are common in patients with diffuse SSc but are uncommon in those with limited disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/2-6,8,13,21,43,56-58\">",
"     2-6,8,13,21,43,56-58",
"    </a>",
"    ]. In one series of 536 patients with limited SSc, for example, only 7 had a peripheral neuropathy not attributable to another cause [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excluding the entrapment neuropathies, a symmetric, sensory polyneuropathy is the neuropathy most frequently associated with SSc. Mononeuropathy or mononeuritis multiplex may occur as a manifestation of vasculitis and is more frequent in patients with limited SSc (the CREST syndrome [Calcinosis cutis Raynaud phenomenon Esophageal dysmotility Sclerodactyly Telangiectasia]) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/2-6,8,13,21,43,56-58\">",
"     2-6,8,13,21,43,56-58",
"    </a>",
"    ]. Because vasculitis is not a typical manifestation of SSc, another overlapping disease, such as systemic lupus erythematosus (SLE), or a concomitant disease, such as cryoglobulinemia due to hepatitis C infection, should be considered in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few reports of peripheral nerve pathology in patients with SSc and neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/14,59-61\">",
"     14,59-61",
"    </a>",
"    ]. Findings in biopsied nerves include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,58,62,63\">",
"     8,58,62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased collagen and amorphous substance in the endoneurium",
"     </li>",
"     <li>",
"      Loss of myelinated fibers",
"     </li>",
"     <li>",
"      Intimal thickening, adventitial edema, and diffuse hyalinosis of endoneurial and perineurial blood vessels",
"     </li>",
"     <li>",
"      Necrotizing vasculitis (very rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory polyneuropathy &mdash; As mentioned, a distal, symmetric, sensory axonal polyneuropathy is the most common type observed in patients with SSc. The significance of subtle neurophysiologic changes which have been observed in patients with no neurologic symptoms is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/3,5,8,56\">",
"       3,5,8,56",
"      </a>",
"      ]. Abnormal nerve conduction may occur at sites where there is no cutaneous sclerosis, suggesting a mechanism other than nerve compression [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mixed sensory and motor polyneuropathy &mdash; Sensorimotor polyneuropathy can also be observed. In one series of 50 patients with SSc, 14 percent had a sensorimotor polyneuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4\">",
"       4",
"      </a>",
"      ]. As with other neurologic manifestations, this abnormality may present prior to the diagnosis of SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,59,65,66\">",
"       4,59,65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mononeuritis multiplex &mdash; Rarely, infarction of peripheral nerves due to inflammation of the vasa nervorum may lead to mononeuritis multiplex [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/3,4,62,67,68\">",
"       3,4,62,67,68",
"      </a>",
"      ]. This vasculitic neuropathy may be more likely if the patient has both SSc and Sj&ouml;gren's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brachial plexopathy &mdash; Brachial plexopathy also has been reported in association with SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cutaneous neuropathies &mdash; Cutaneous neuropathies can develop in sclerodermatous or non-sclerodermatous areas of skin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8\">",
"       8",
"      </a>",
"      ]. Tactile abnormalities are more common in the feet than in the hands and are more common at the fingertips than on the palms.",
"      <br/>",
"      <br/>",
"      Clinical manifestations of a cutaneous neuropathy may be observed despite the absence of objective abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8\">",
"       8",
"      </a>",
"      ]; conversely, histologic evidence of damage can be seen upon examination of clinically uninvolved skin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate etiologies should be considered in patients who develop clinical peripheral neuropathies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    .) These include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Connective tissue diseases",
"     </li>",
"     <li>",
"      Paraneoplastic syndromes",
"     </li>",
"     <li>",
"      Paraproteinemia",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Drug or environmental toxicities",
"     </li>",
"     <li>",
"      Familial neuropathies",
"     </li>",
"     <li>",
"      Vitamin deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no specific findings on neurophysiologic studies that distinguish the peripheral neuropathy of SSc from other diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin B12 deficiency should be considered in patients with SSc of the intestine and resultant malabsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of sensory and sensorimotor polyneuropathy in the patient with SSc that is not due to vasculitis or multiple nerve entrapments is similar to that of neuropathy in patients with other rheumatic diseases. If the polyneuropathy is associated with systemic vasculitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids are the usual initial regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of polyneuropathy\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     AUTONOMIC NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal gastrointestinal motility in patients with SSc is due in part to autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/15,71-73\">",
"     15,71-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .) Autonomic dysfunction also possibly contributes to impotence, which occurs frequently in SSc patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,74-76\">",
"     8,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evidence of sympathetic and parasympathetic dysfunction of cardiovascular reflexes is also common; however, this is rarely clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8,77-80\">",
"     8,77-80",
"    </a>",
"    ]. In addition, an abnormal or absent sympathetic skin response has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/56,81\">",
"     56,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complaint of muscle weakness is quite common in those with SSc, being reported in over 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The areas most affected are frequently located in the vicinity of involved joints and skin, but this finding does not necessarily reflect underlying muscle disease. Nevertheless, both a myopathy and myositis have been observed. In addition, muscle weakness and atrophy may arise from disuse.",
"   </p>",
"   <p>",
"    Cardiac involvement was more frequent in patients with skeletal muscle disease in a case-control study, which compared 40 SSc patients with myopathy (muscle weakness or myalgia associated with elevation of CK more than five times the upper limit of normal, myopathic changes on EMG, or abnormal muscle pathology) with SSc patients without myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/84\">",
"     84",
"    </a>",
"    ]. Cardiac involvement, defined as arrhythmia or conduction abnormalities, clinical heart failure, or left ventricular ejection fraction less than 60, was more common in the patients with myositis (odds ratio 2.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild, indolent type of proximal myopathy has been described in patients with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,5,13,19,85\">",
"     4,5,13,19,85",
"    </a>",
"    ]. It is associated with the following laboratory and diagnostic test results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,82,86\">",
"     4,82,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insignificant elevations in the creatine kinase (CK) levels",
"     </li>",
"     <li>",
"      Decreased duration of motor unit potential on electromyography (EMG)",
"     </li>",
"     <li>",
"      Increased frequency of polyphasic motor units",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Muscle biopsy specimens reveal mild abnormalities, including increased connective tissue, proliferation of intima in endomysial and perimysial blood vessels, and occasional perivascular infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/85,87,88\">",
"     85,87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indolent proximal type of myopathy is usually nonprogressive; immunosuppressive therapy is ineffective and is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SSc may develop an inflammatory myopathy clinically and histologically similar to classic polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,5,8,82,85,88\">",
"     4,5,8,82,85,88",
"    </a>",
"    ]. This should be suspected if any of the following features are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weakness is progressive or severe.",
"     </li>",
"     <li>",
"      CK level is over twice normal.",
"     </li>",
"     <li>",
"      EMG studies reveal abnormalities suggestive of myositis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by muscle biopsy. Inclusion body myositis is rarely reported in association with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4\">",
"     4",
"    </a>",
"    ]. Some of these patients develop myofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is similar to that of classic polymyositis; this includes glucocorticoids with or without cytotoxic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients should also be evaluated for possible cardiac involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Muscle weakness'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drug-induced muscle disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced muscle disease is a consideration in patients with SSc whose weakness develops in conjunction with therapeutic use of agents known to cause myopathy, myositis, or neuromuscular junction disease (see below). Among the offending agents are D-penicillamine, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , and antimalarial drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuromuscular junction dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The co-occurrence of SSc and myasthenia gravis, in the absence of drugs that can cause neuromuscular junction dysfunction, has been reported in a small number of patients. In a report of two cases and a review of 12 others, the overwhelming majority was women, and most had seropositive myasthenia gravis (ie, positive serum antibodies to either the acetylcholine receptor [AChR] or to muscle tyrosine kinase [MuSk]) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported central nervous system (CNS) manifestations of SSc range in severity from annoying (such as headache and radiculopathy) to life-threatening (including seizures, stroke, vasculitis, and myelopathy). Serious abnormalities are relatively rare.",
"   </p>",
"   <p>",
"    However, these features may only be associations and may not directly result from pathogenic mechanisms unique to SSc. In autopsy studies, for example, evidence of brain injury or ischemia occurred in similar proportions in both patients and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/87,90\">",
"     87,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether there is an increased prevalence of migraine headache in patients with SSc. In one study of 36 SSc patients and 26 control individuals, an enhanced incidence of migraine headaches was reported in SSc patients (32 and 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/91\">",
"     91",
"    </a>",
"    ]. However, an earlier study failed to find an association [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/92\">",
"     92",
"    </a>",
"    ]. Headache is treated in a similar fashion as that for patients without SSc, with the exception that ergot alkaloids and other vasoconstricting drugs are avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of patients with both SSc and seizures; however, no clear evidence for a unifying pathogenesis exists [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/6,93,94\">",
"     6,93,94",
"    </a>",
"    ]. In a series of 155 SSc patients, five had generalized or focal seizures, which were most likely due to systemic complications of SSc (such as malignant hypertension and uremia) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/2\">",
"     2",
"    </a>",
"    ]. In another series of 727 patients, six had seizures, an incidence similar to that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct causal relationship between SSc and stroke has also not been adequately demonstrated. Ischemic and hemorrhagic infarcts have been reported in patients with both diffuse and limited SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,36,95-99\">",
"     4,36,95-99",
"    </a>",
"    ]. In most cases, strokes were due to an atherosclerotic or hypertensive mechanism rather than directly due to SSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic findings associated with stroke are present at approximately the same frequency at autopsy in SSc and non-scleroderma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/87,90\">",
"     87,90",
"    </a>",
"    ]. The brain and cerebral vasculature reveal medial and intimal hyperplasia and fibrosis generally without inflammatory cell infiltrates, which is located in the carotid artery or in medium- or small-sized intracranial arteries and arterioles [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, cerebral arterial wall calcifications may be relatively specific for SSc, even in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/100\">",
"     100",
"    </a>",
"    ]. In one study, a head CT was performed in 37 consecutive patients with SSc as well as in 74 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/101\">",
"     101",
"    </a>",
"    ]. Intracerebral calcification was reported in 32 and 9 percent of SSc patients and controls, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Central nervous system vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system vasculitis is a rare complication of SSc, with most patients diagnosed without a brain biopsy and solely on the basis of findings with cerebral angiography, an approach which leaves the diagnosis uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/95,98,99,102,103\">",
"     95,98,99,102,103",
"    </a>",
"    ]. Improvement has been observed with glucocorticoid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/99,102,103\">",
"     99,102,103",
"    </a>",
"    ]. If CNS vasculitis is strongly suggested angiographically or is confirmed by biopsy, treatment is the same as that for patients with isolated CNS vasculitis without SSc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In SSc, radiculopathy can be due to nerve root compression by vertebral destruction or epidural calcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of myelopathy among patients with SSc may include impaired vibratory sense, band-like paresthesias, hyperreflexia, impotence, and quadriparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/4,104-108\">",
"     4,104-108",
"    </a>",
"    ]. Findings may present acutely or indolently. In two reported cases, a transverse myelopathy developed acutely and improved after therapy with glucocorticoids. One of these patients was also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/104,109\">",
"     104,109",
"    </a>",
"    ]. Rarely, spinal cord compression may occur due to calcinosis in the spinal epidural space [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/105,108,110,111\">",
"     105,108,110,111",
"    </a>",
"    ]. Both paraspinal and intraspinal calcinosis can occur and are usually asymptomatic, but they may cause changes including paraplegia and sensory deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     MR imaging abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinically significant CNS manifestations due to SSc are relatively rare, sensitive imaging techniques such as magnetic resonance (MR) imaging may detect abnormalities in asymptomatic patients that are of uncertain clinical significance. This was illustrated by two studies that included a total of 51 patients and 53 healthy age and sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/48/778/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. None of the patients had a history of CNS disease or symptoms to suggest CNS dysfunction. In the first report, hyperintense lesions located in white matter were significantly more numerous in patients than in controls. The number of regions of T2-weighted hyperintensity was not dependent upon age or disease duration. In the second report, there was no significant difference in white matter hyperintensities between patients and controls. However, patients with abnormal MRI findings were significantly younger than controls.",
"   </p>",
"   <p>",
"    While the pathogenesis and clinical significance of regions of increased white-matter T2-weighted signal in asymptomatic patients are uncertain, the high prevalence suggests caution in making therapeutic decisions based on the presence or absence of similar &ldquo;lesions&rdquo; in patients with symptoms of CNS dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26846911\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic involvement in systemic sclerosis (SSc; scleroderma) includes cranial, entrapment, peripheral, cutaneous, and autonomic neuropathies; myopathy; and central nervous system involvement, including headache, seizures, stroke, vascular disease, radiculopathy, and myelopathy. Estimates of the frequency of neurologic involvement in patients with SSc vary widely, but central nervous system (CNS) involvement due to SSc is rare. Complications of other organ damage in SSc, such as renal failure, uncontrolled hypertension, and heart or respiratory failure, may have neurologic manifestations. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible mechanisms of neuropathy in SSc include vascular, compression-dependent, and autoimmune processes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cranial neuropathies have been described in patients with SSc. The most commonly involved is the trigeminal nerve, with dysfunction of the optic, oculomotor, trochlear, abducens, facial, glossopharyngeal, and auditory nerves also being reported. Symptoms of trigeminal neuropathy include slowly progressive unilateral or bilateral facial numbness, frequently with associated pain and paresthesia. However, the differential diagnosis of isolated facial numbness is broad. In trigeminal neuropathy, the administration of glucocorticoids is probably not beneficial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cranial neuropathies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Trigeminal neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common of the entrapment neuropathies is compression of the median nerve at the wrist or carpal tunnel syndrome. Nerves at other sites are less frequently involved. CTS sometimes presents prior to the diagnosis of limited or diffuse SSc. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Entrapment neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The peripheral polyneuropathies, consisting of sensory, mixed sensory and motor, and mononeuritis multiplex, are common in patients with diffuse SSc but are uncommon in those with limited disease. Excluding the entrapment neuropathies, a symmetric, sensory polyneuropathy is the neuropathy most frequently associated with SSc. Mononeuropathy or mononeuritis multiplex may occur as a manifestation of vasculitis and is more frequent in patients with limited SSc. Because vasculitis is not a typical manifestation of SSc, another overlapping disease, such as systemic lupus erythematosus, or a concomitant disease, such as cryoglobulinemia due to hepatitis C infection, should be considered in this setting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Peripheral polyneuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal gastrointestinal motility in patients with SSc is due, in part, to autonomic dysfunction. Autonomic dysfunction also possibly contributes to impotence, which occurs frequently in SSc patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Autonomic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complaint of muscle weakness is quite common in those with SSc, being reported in over 80 percent of patients. The areas most affected are frequently located in the vicinity of involved joints and skin, but this finding does not necessarily reflect underlying muscle disease. Both a myopathy and myositis have been observed. An increased frequency of cardiac disease has been reported in association with SSc-related myositis. In addition, muscle weakness and atrophy may arise from disuse. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reported central nervous system (CNS) manifestations of SSc range in severity from annoying (such as headache and radiculopathy) to life-threatening (including seizures, stroke, vasculitis, and myelopathy). Serious abnormalities are relatively rare. However, these features may only be associations and may not directly result from pathogenic mechanisms unique to SSc. In autopsy studies, for example, evidence of brain injury or ischemia occurred in similar proportions in both patients and controls. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Central nervous system involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/1\">",
"      TUFFANELLI DL, WINKELMANN RK. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol 1961; 84:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/2\">",
"      Gordon RM, Silverstein A. Neurologic manifstations in progressive systemic sclerosis. Arch Neurol 1970; 22:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/3\">",
"      Lee P, Bruni J, Sukenik S. Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol 1984; 11:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/4\">",
"      Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 1992; 49:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/5\">",
"      Hietaharju A, J&auml;&auml;skel&auml;inen S, Kalimo H, Hietarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve 1993; 16:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/6\">",
"      Hietaharju A, J&auml;ntti V, Korpela M, Frey H. Nervous system involvement in systemic lupus erythematosus, Sj&ouml;gren syndrome and scleroderma. Acta Neurol Scand 1993; 88:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/7\">",
"      Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52:2873.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenbaum RB, Campbell SM, Rosenbaum JT. Clinical Neurology of Rheumatic Diseases, Butterworth-Heinemann, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/9\">",
"      Holland KE, Steffes B, Nocton JJ, et al. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117:e132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/10\">",
"      Chung MH, Sum J, Morrell MJ, Horoupian DS. Intracerebral involvement in scleroderma en coup de sabre: report of a case with neuropathologic findings. Ann Neurol 1995; 37:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/11\">",
"      David J, Wilson J, Woo P. Scleroderma 'en coup de sabre'. Ann Rheum Dis 1991; 50:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/12\">",
"      Kanzato N, Matsuzaki T, Komine Y, et al. Localized scleroderma associated with progressing ischemic stroke. J Neurol Sci 1999; 163:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/13\">",
"      Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol 1994; 23:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/14\">",
"      Di Trapani G, Tulli A, La Cara A, et al. Peripheral neuropathy in course of progressive systemic sclerosis. Light and ultrastructural study. Acta Neuropathol 1986; 72:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/15\">",
"      Cerinic MM, Generini S, Pignone A, Casale R. The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. Rheum Dis Clin North Am 1996; 22:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/16\">",
"      Zeballos RS, Fox RI, Cheresh DA, McPherson RA. Anti-glycosphingolipid autoantibodies in rheumatologic disorders. J Clin Lab Anal 1994; 8:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/17\">",
"      Ashworth B, Tait GB. Trigeminal neuropathy in connective tissue disease. Neurology 1971; 21:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/18\">",
"      Farrell DA, Medsger TA Jr. Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 1982; 73:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/19\">",
"      Teasdall RD, Frayha RA, Shulman LE. Cranial nerve involvement in systemic sclerosis (scleroderma): a report of 10 cases. Medicine (Baltimore) 1980; 59:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/20\">",
"      Beighton P, Gumpel JM, Cornes NG. Prodromal trigeminal sensory neuropathy in progressive systemic sclerosis. Ann Rheum Dis 1968; 27:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/21\">",
"      Berth-Jones J, Coates PA, Graham-Brown RA, Burns DA. Neurological complications of systemic sclerosis--a report of three cases and review of the literature. Clin Exp Dermatol 1990; 15:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/22\">",
"      Hagen NA, Stevens JC, Michet CJ Jr. Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 1990; 40:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/23\">",
"      Jimenez-Moreno J, Selva-O'Callaghan A, Rovira-Ca&ntilde;ellas A, et al. Trigeminal sensory neuropathy in systemic sclerosis. Br J Rheumatol 1998; 37:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/24\">",
"      Lecky BR, Hughes RA, Murray NM. Trigeminal sensory neuropathy. A study of 22 cases. Brain 1987; 110 ( Pt 6):1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/25\">",
"      Kabadi UM, Sinkoff MW. Trigeminal neuralgia in progressive systemic sclerosis. Postgrad Med 1977; 61:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/26\">",
"      Tait B, Ashworth B. Trigeminal neuropathy in connective tissue disease. Ann Rheum Dis 1970; 29:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/27\">",
"      Casey EB, Lawton NF. Progressive systemic sclerosis presenting with Raynaud's phenomenon in the tongue and sensory trigeminal neuropathy. Rheumatol Phys Med 1971; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/28\">",
"      Burke MJ, Carty JE. Trigeminal neuropathy as the presenting symptom of systemic sclerosis. Postgrad Med J 1979; 55:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/29\">",
"      Heald A. Progressive systemic sclerosis presenting as a case of trigeminal neuropathy. J Neurol Neurosurg Psychiatry 1989; 52:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/30\">",
"      Thompson PD, Robertson GJ. Trigeminal neuropathy heralding scleroderma. A report of a case. J Maine Med Assoc 1973; 64:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/31\">",
"      Vicente A, Herrero C, Mart&iacute;n E, et al. Trigeminal sensory-neuropathy in systemic sclerosis. Clin Exp Dermatol 1991; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/32\">",
"      Olney RK. Neuropathies associated with connective tissue disease. Semin Neurol 1998; 18:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/33\">",
"      Berrettini S, Ferri C, Pitaro N, et al. Audiovestibular involvement in systemic sclerosis. ORL J Otorhinolaryngol Relat Spec 1994; 56:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/34\">",
"      Amor-Dorado JC, Arias-Nu&ntilde;ez MC, Miranda-Filloy JA, et al. Audiovestibular manifestations in patients with limited systemic sclerosis and centromere protein-B (CENP-B) antibodies. Medicine (Baltimore) 2008; 87:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/35\">",
"      Boschi A, Snyers B, Lambert M. Bilateral optic neuropathy associated with the crest variant of scleroderma. Eur J Ophthalmol 1993; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/36\">",
"      Hietaharju A, J&auml;&auml;skel&auml;inen S, Hietarinta M, Frey H. Central nervous system involvement and psychiatric manifestations in systemic sclerosis (scleroderma): clinical and neurophysiological evaluation. Acta Neurol Scand 1993; 87:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/37\">",
"      Ortiz JR, Newman NJ, Barrow DL. CREST-associated multiple intracranial aneurysms and bilateral optic neuropathies. J Clin Neuroophthalmol 1991; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/38\">",
"      Trostle DC, Helfrich D, Medsger TA Jr. Systemic sclerosis (scleroderma) and multiple sclerosis. Arthritis Rheum 1986; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/39\">",
"      Arnett FC, Michels RG. Inflammatory ocular myopathy in systemic sclerosis (scleroderma). A case report and review of the literature. Arch Intern Med 1973; 132:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/40\">",
"      Campbell WW, Bajandas FJ. Restrictive ophthalmopathy associated with linear scleroderma. J Neuroophthalmol 1995; 15:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/41\">",
"      Mejias E. Superior oblique muscle paralysis in the CREST syndrome. P R Health Sci J 1986; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/42\">",
"      Rush JA. Isolated superior oblique paralysis in progressive systemic sclerosis. Ann Ophthalmol 1981; 13:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/43\">",
"      Lori S, Matucci-Cerinic M, Casale R, et al. Peripheral nervous system involvement in systemic sclerosis: the median nerve as target structure. Clin Exp Rheumatol 1996; 14:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/44\">",
"      Machet L, Vaillant L, Machet MC, et al. Carpal tunnel syndrome and systemic sclerosis. Dermatology 1992; 185:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/45\">",
"      Mondelli M, Romano C, Della Porta PD, Rossi A. Electrophysiological evidence of \"nerve entrapment syndromes\" and subclinical peripheral neuropathy in progressive systemic sclerosis (scleroderma). J Neurol 1995; 242:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/46\">",
"      Pal B. Carpal tunnel syndrome as a herald of autoimmune rheumatic disorders. J R Soc Med 1997; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/47\">",
"      Barr WG, Blair SJ. Carpal tunnel syndrome as the initial manifestation of scleroderma. J Hand Surg Am 1988; 13:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/48\">",
"      Gonz&aacute;lez-Alvaro I, Carvajal I, Estevez M, et al. Carpal tunnel syndrome as initial manifestation of inflammatory connective tissue diseases. Ann Rheum Dis 1995; 54:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/49\">",
"      Quinones CA, Perry HO, Rushton JG. Carpal tunnel syndrome in dermatomyositis and scleroderma. Arch Dermatol 1966; 94:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/50\">",
"      Sukenik S, Abarbanel JM, Buskila D, et al. Impotence, carpal tunnel syndrome and peripheral neuropathy as presenting symptoms in progressive systemic sclerosis. J Rheumatol 1987; 14:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/51\">",
"      Thurman RT, Jindal P, Wolff TW. Ulnar nerve compression in Guyon's canal caused by calcinosis in scleroderma. J Hand Surg Am 1991; 16:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/52\">",
"      Chammas M, Meyer zu Reckendorf G, Allieu Y. Compression of the ulnar nerve in Guyon's canal by pseudotumoral calcinosis in systemic scleroderma. J Hand Surg Br 1995; 20:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/53\">",
"      Polio JL, Stern PJ. Digital nerve calcification in CREST syndrome. J Hand Surg Am 1989; 14:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/54\">",
"      Kaufmann J, Canoso JJ. Progressive systemic sclerosis and meralgia paraesthetica. Ann Intern Med 1986; 105:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/55\">",
"      Langevitz P, Buskila D, Lee P. Ilioinguinal nerve entrapment in a patient with systemic sclerosis (scleroderma). Clin Rheumatol 1993; 12:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/56\">",
"      Schady W, Sheard A, Hassell A, et al. Peripheral nerve dysfunction in scleroderma. Q J Med 1991; 80:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/57\">",
"      Dierckx RA, Aichner F, Gerstenbrand F, Fritsch P. Progressive systemic sclerosis and nervous system involvement. A review of 14 cases. Eur Neurol 1987; 26:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/58\">",
"      Dyck PJ, Hunder GG, Dyck PJ. A case-control and nerve biopsy study of CREST multiple mononeuropathy. Neurology 1997; 49:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/59\">",
"      Corbo M, Nemni R, Iannaccone S, et al. Peripheral neuropathy in scleroderma. Clin Neuropathol 1993; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/60\">",
"      Nitta Y, Sobue G. Progressive systemic sclerosis associated with multiple mononeuropathy. Dermatology 1996; 193:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/61\">",
"      RICHTER RB. Peripheral neuropathy and connective tissue disease. J Neuropathol Exp Neurol 1954; 13:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/62\">",
"      Oddis CV, Eisenbeis CH Jr, Reidbord HE, et al. Vasculitis in systemic sclerosis: association with Sj&ouml;gren's syndrome and the CREST syndrome variant. J Rheumatol 1987; 14:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/63\">",
"      Said G, Lacroix-Ciaudo C, Fujimura H, et al. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/64\">",
"      Poncelet AN, Connolly MK. Peripheral neuropathy in scleroderma. Muscle Nerve 2003; 28:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/65\">",
"      Knupp-Oliveira S, Cerinic MM. Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). Scand J Rheumatol 1999; 28:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/66\">",
"      Sant SM, Murphy GM. Neurotropic ulceration in systemic sclerosis. Clin Exp Dermatol 1994; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/67\">",
"      Leichenko T, Herrick AL, Alani SM, et al. Mononeuritis in two patients with limited cutaneous systemic sclerosis. Br J Rheumatol 1994; 33:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/68\">",
"      Goldsmith PC, Fowler CJ, Snaith ML, Dowd PM. Morphoea and mononeuritis multiplex. J R Soc Med 1991; 84:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/69\">",
"      Allanore Y, Zuber M, Kahan A. Brachial plexopathy associated with systemic sclerosis. Clin Rheumatol 2002; 21:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/70\">",
"      PAWLOWSKI A. THE NERVE NETWORK OF THE SKIN IN DIFFUSE SCLERODERMA AND CLINICALLY SIMILAR CONDITIONS. Arch Dermatol 1963; 88:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/71\">",
"      Akesson A, Gustafson T, Wollheim F, Brismar J. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987; 16:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/72\">",
"      Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989; 96:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/73\">",
"      Lock G, Straub RH, Zeuner M, et al. Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol 1998; 25:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/74\">",
"      Klein LE, Posner MS. Progressive systemic sclerosis and impotence. Ann Intern Med 1981; 95:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/75\">",
"      Lally EV, Jimenez SA. Impotence in progressively systemic sclerosis. Ann Intern Med 1981; 95:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/76\">",
"      Nowlin NS, Brick JE, Weaver DJ, et al. Impotence in scleroderma. Ann Intern Med 1986; 104:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/77\">",
"      Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol 1997; 36:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/78\">",
"      Klimiuk PS, Taylor L, Baker RD, Jayson MI. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 1988; 47:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/79\">",
"      Sonnex C, Paice E, White AG. Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients. Ann Rheum Dis 1986; 45:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/80\">",
"      Straub RH, Zeuner M, Lock G, et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/81\">",
"      Raszewa M, Hausmanowa-Petrusewicz I, Baszczyk M, Jaboska S. Sympathetic skin response in scleroderma. Electromyogr Clin Neurophysiol 1991; 31:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/82\">",
"      Clements PJ, Furst DE, Campion DS, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978; 21:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/83\">",
"      Medsger TA Jr, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968; 11:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/84\">",
"      Ranque B, B&eacute;rezn&eacute; A, Le-Guern V, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol 2010; 39:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/85\">",
"      Brick JE, Brick JF. Neurologic manifestations of rheumatologic disease. Neurol Clin 1989; 7:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/86\">",
"      Hausmanowa-Petrusewicz I, Jaboska S, Baszczyk M, Matz B. Electromyographic findings in various forms of progressive systemic sclerosis. Arthritis Rheum 1982; 25:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/87\">",
"      D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/88\">",
"      Ringel RA, Brick JE, Brick JF, et al. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990; 150:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/89\">",
"      Zivkovi SA, Medsger TA Jr. Myasthenia gravis and scleroderma: two cases and a review of the literature. Clin Neurol Neurosurg 2007; 109:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/90\">",
"      PIPER WN, HELWIG EB. Progressive systemic sclerosis; visceral manifestations in generalized scleroderma. AMA Arch Derm 1955; 72:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/91\">",
"      Pal B, Gibson C, Passmore J, et al. A study of headaches and migraine in Sj&ouml;gren's syndrome and other rheumatic disorders. Ann Rheum Dis 1989; 48:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/92\">",
"      Goldberg NC, Duncan SC, Winkelmann RK. Migraine and systemic scleroderma. Arch Dermatol 1978; 114:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/93\">",
"      Bhardwaj A, Badesha PS. Seizures in a patient with diffuse scleroderma. Postgrad Med J 1995; 71:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/94\">",
"      Pupillo G, Andermann F, Dubeau F. Linear scleroderma and intractable epilepsy: neuropathologic evidence for a chronic inflammatory process. Ann Neurol 1996; 39:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/95\">",
"      Lee JE, Haynes JM. Carotid arteritis and cerebral infarction due to scleroderma. Neurology 1967; 17:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/96\">",
"      Andonopoulos AP, Maraziotis T, Rigas G, et al. Multiple spontaneous intracerebral hemorrhages in a patient with progressive systemic sclerosis. Rev Rhum Engl Ed 1998; 65:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/97\">",
"      Merino J, Casanueva B, Piney E, et al. Hemiplegia and peripheral gangrene secondary to large and medium size vessels involvement in C.R.E.S.T. syndrome. Clin Rheumatol 1982; 1:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/98\">",
"      Miller SB, Lo HH, Campbell WG. Clinicopathologic conference. Grady Memorial Hospital--Emory University. Progressive systemic sclerosis with terminal neurologic manifestations. South Med J 1981; 74:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/99\">",
"      Pathak R, Gabor AJ. Scleroderma and central nervous system vasculitis. Stroke 1991; 22:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/100\">",
"      H&eacute;ron E, Fornes P, Rance A, et al. Brain involvement in scleroderma: two autopsy cases. Stroke 1998; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/101\">",
"      Heron E, Hernigou A, Chatellier G, et al. Intracerebral calcification in systemic sclerosis. Stroke 1999; 30:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/102\">",
"      Estey E, Lieberman A, Pinto R, et al. Cerebral arteritis in scleroderma. Stroke 1979; 10:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/103\">",
"      Ishida K, Kamata T, Tsukagoshi H, Tanizaki Y. Progressive systemic sclerosis with CNS vasculitis and cyclosporin A therapy. J Neurol Neurosurg Psychiatry 1993; 56:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/104\">",
"      Brown JJ, Murphy MJ. Transverse myelopathy in progressive systemic sclerosis. Ann Neurol 1985; 17:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/105\">",
"      Bracard S, Thomas E, Braun M, et al. Cervical cord compression in scleroderma. One case. J Neuroradiol 1991; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/106\">",
"      Clement GB, Grizzard K, Vasey FB, et al. Neuropathic arthropathy (Charcot joints) due to cervical osteolysis: a complication of progressive systemic sclerosis. J Rheumatol 1984; 11:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/107\">",
"      KAPLAN A, MATLES A. Compression of the thoracic spinal cord in a patient with scleroderma. Bull Hosp Joint Dis 1957; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/108\">",
"      Pinstein ML, Sebes JI, Leventhal M, Robertson JT. Case report 579: Progressive systemic sclerosis (PSS) with cervical cord compression syndrome, osteolysis and bilateral facet arthropathy. Skeletal Radiol 1989; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/109\">",
"      Franciotta D, Zardini E, Caporali R, et al. Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. J Neurol Sci 2011; 303:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/110\">",
"      Petrocelli AR, Bassett LW, Mirra J, et al. Scleroderma: dystrophic calcification with spinal cord compression. J Rheumatol 1988; 15:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/111\">",
"      Haverbush TJ, Wilde AH, Hawk WA Jr, Scherbel AL. Osteolysis of the ribs and cervical spine in progressive systemic sclerosis (scleroderma). A case report. J Bone Joint Surg Am 1974; 56:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/112\">",
"      Ogawa T, Ogura T, Ogawa K, et al. Paraspinal and intraspinal calcinosis: frequent complications in patients with systemic sclerosis. Ann Rheum Dis 2009; 68:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/113\">",
"      Sardanelli F, Iozzelli A, Cotticelli B, et al. White matter hyperintensities on brain magnetic resonance in systemic sclerosis. Ann Rheum Dis 2005; 64:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/48/778/abstract/114\">",
"      Argyropoulou MI, Tsifetaki N, Zikou AK, et al. Systemic sclerosis: brain abnormalities revealed by conventional magnetic resonance imaging and magnetization transfer imaging. Arthritis Rheum 2006; 54:1350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7550 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_778=[""].join("\n");
var outline_f0_48_778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26846911\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRANIAL NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trigeminal neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical manifestations and findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other cranial neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ENTRAPMENT NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other compressive neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PERIPHERAL POLYNEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      AUTONOMIC NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Myositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drug-induced muscle disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuromuscular junction dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CENTRAL NERVOUS SYSTEM INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Central nervous system vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      MR imaging abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26846911\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_48_779="Patients to ask about violence";
var content_f0_48_779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patients who should be asked about domestic violence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Female trauma victims",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female emergency room patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with chronic abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with chronic headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnant women, especially with injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with sexually transmitted diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elders with evidence of neglect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elders with injuries",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_779=[""].join("\n");
var outline_f0_48_779=null;
var title_f0_48_780="Desirable clinician behaviors";
var content_f0_48_780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Desirable clinician behaviors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Getting the visit off to a good start",
"       </td>",
"       <td class=\"subtitle1\">",
"        Finding out what the problem is",
"       </td>",
"       <td class=\"subtitle1\">",
"        Talking about problem/what to do about it",
"       </td>",
"       <td class=\"subtitle1\">",
"        Following up on problem and treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Professionalism",
"       </td>",
"       <td>",
"        Appearance",
"       </td>",
"       <td>",
"        Preparation by clinician",
"       </td>",
"       <td>",
"        Clear/complete explanations",
"       </td>",
"       <td>",
"        Providing access and coverage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carry-over from previous patients",
"       </td>",
"       <td>",
"        Limit interruptions",
"       </td>",
"       <td>",
"        Clinician knows limitations",
"       </td>",
"       <td>",
"        Following through",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Respect",
"       </td>",
"       <td>",
"        Punctuality",
"       </td>",
"       <td>",
"        Listens and understands",
"       </td>",
"       <td>",
"        Involves patient in treatment",
"       </td>",
"       <td>",
"        Involves patient in management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treats like an equal",
"       </td>",
"       <td>",
"        Explains exam",
"       </td>",
"       <td>",
"        Honesty",
"       </td>",
"       <td>",
"        Conscious of financial situations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Support",
"       </td>",
"       <td>",
"        Courtesy",
"       </td>",
"       <td>",
"        Takes complaints seriously",
"       </td>",
"       <td>",
"        Taking time to talk",
"       </td>",
"       <td>",
"        Checks on patients at home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relaxed atmosphere",
"       </td>",
"       <td>",
"        Concerned about daily life",
"       </td>",
"       <td>",
"        Encourages questions",
"       </td>",
"       <td>",
"        Checks on what patient should be doing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_780=[""].join("\n");
var outline_f0_48_780=null;
var title_f0_48_781="Drug causes of pemphigoid";
var content_f0_48_781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that may induce bullous pemphigoid or mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinomycin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arsenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azapropazone (NSAID, not currently available)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Captopril (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipeptidyl peptidase-4 inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enalapril",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etanercept",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flupenthixol (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide (sulfonamide*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gold thiosulfate (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interleukin-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Losartan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mefenamic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyldopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nadolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omeprazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillamine (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillins, including amoxicillin and ampicillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenacetin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental extracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium iodide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoralens with ultraviolet A (PUVA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine (sulfonamide*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfamethoxazole&nbsp;(sulfonamide*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terbinafine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiopronin (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiobutarit, D Penicillamine analog (thiol*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolbutamide (sulfonamide*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Topical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anthralin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzyl benzoate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coal tar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-fluorouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodophor in adhesive bandage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idoxuridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pilocarpine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timolol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Thiol compounds and sulfonamide derivatives are common inducers of pemphigoid.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Vassileva S. Drug-induced pemphigoid: Bullous and cicatricial. Clin Dermatol 1998; 16:379. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_781=[""].join("\n");
var outline_f0_48_781=null;
var title_f0_48_782="Induced pluripotent stem cells in therapy";
var content_f0_48_782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Induced pluripotent stem cells (iPS) in cellular replacement therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Principle of use of induced pluripotent stem cells (iPS) in cellular replacement therapy. Patient cells, ie skin fibroblasts, can be obtained and reprogrammed to pluripotency ex vivo, generating iPS. These iPS can subsequently be differentiated to specific cell types which can be used for autologous transplantation. In monogenic diseases, it may be possible to correct the disease gene in iPS before transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_782=[""].join("\n");
var outline_f0_48_782=null;
var title_f0_48_783="Structure recombinant TPO";
var content_f0_48_783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of the recombinant thrombopoietins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: rHuTPO (recombinant human thrombopoietin) (left) has a molecular structure identical to native thrombopoietin and is fully glycoslyated. It consists of a carbohydrate-rich terminal domain (upper box) and an \"erythropoietin-like\" domain (lower box) which contains the receptor-binding region. Right panel: PEG-rHuMGDF (megakaryocyte growth and development factor) consists of the \"erythropoietin-like\" domain only and is stabilized by the presence of a 20 kDa polyethylene glycol moiety on the amino terminus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Amgen, Inc, Thousand Oaks, California.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_48_783=[""].join("\n");
var outline_f0_48_783=null;
